Lipoproteins: Lipid-protein complexes involved in the transportation and metabolism of lipids in the body. They are spherical particles consisting of a hydrophobic core of TRIGLYCERIDES and CHOLESTEROL ESTERS surrounded by a layer of hydrophilic free CHOLESTEROL; PHOSPHOLIPIDS; and APOLIPOPROTEINS. Lipoproteins are classified by their varying buoyant density and sizes.Lipoproteins, LDL: A class of lipoproteins of small size (18-25 nm) and light (1.019-1.063 g/ml) particles with a core composed mainly of CHOLESTEROL ESTERS and smaller amounts of TRIGLYCERIDES. The surface monolayer consists mostly of PHOSPHOLIPIDS, a single copy of APOLIPOPROTEIN B-100, and free cholesterol molecules. The main LDL function is to transport cholesterol and cholesterol esters to extrahepatic tissues.Lipoproteins, HDL: A class of lipoproteins of small size (4-13 nm) and dense (greater than 1.063 g/ml) particles. HDL lipoproteins, synthesized in the liver without a lipid core, accumulate cholesterol esters from peripheral tissues and transport them to the liver for re-utilization or elimination from the body (the reverse cholesterol transport). Their major protein component is APOLIPOPROTEIN A-I. HDL also shuttle APOLIPOPROTEINS C and APOLIPOPROTEINS E to and from triglyceride-rich lipoproteins during their catabolism. HDL plasma level has been inversely correlated with the risk of cardiovascular diseases.Lipoproteins, VLDL: A class of lipoproteins of very light (0.93-1.006 g/ml) large size (30-80 nm) particles with a core composed mainly of TRIGLYCERIDES and a surface monolayer of PHOSPHOLIPIDS and CHOLESTEROL into which are imbedded the apolipoproteins B, E, and C. VLDL facilitates the transport of endogenously made triglycerides to extrahepatic tissues. As triglycerides and Apo C are removed, VLDL is converted to INTERMEDIATE-DENSITY LIPOPROTEINS, then to LOW-DENSITY LIPOPROTEINS from which cholesterol is delivered to the extrahepatic tissues.Lipoprotein Lipase: An enzyme of the hydrolase class that catalyzes the reaction of triacylglycerol and water to yield diacylglycerol and a fatty acid anion. The enzyme hydrolyzes triacylglycerols in chylomicrons, very-low-density lipoproteins, low-density lipoproteins, and diacylglycerols. It occurs on capillary endothelial surfaces, especially in mammary, muscle, and adipose tissue. Genetic deficiency of the enzyme causes familial hyperlipoproteinemia Type I. (Dorland, 27th ed) EC 126.96.36.199.Lipoprotein(a): A lipoprotein that resembles the LOW-DENSITY LIPOPROTEINS but with an extra protein moiety, APOPROTEIN (A) also known as APOLIPOPROTEIN (A), linked to APOLIPOPROTEIN B-100 on the LDL by one or two disulfide bonds. High plasma level of lipoprotein (a) is associated with increased risk of atherosclerotic cardiovascular disease.Receptors, Virus: Specific molecular components of the cell capable of recognizing and interacting with a virus, and which, after binding it, are capable of generating some signal that initiates the chain of events leading to the biological response.Receptors, Immunologic: Cell surface molecules on cells of the immune system that specifically bind surface molecules or messenger molecules and trigger changes in the behavior of cells. Although these receptors were first identified in the immune system, many have important functions elsewhere.Integrins: A family of transmembrane glycoproteins (MEMBRANE GLYCOPROTEINS) consisting of noncovalent heterodimers. They interact with a wide variety of ligands including EXTRACELLULAR MATRIX PROTEINS; COMPLEMENT, and other cells, while their intracellular domains interact with the CYTOSKELETON. The integrins consist of at least three identified families: the cytoadhesin receptors(RECEPTORS, CYTOADHESIN), the leukocyte adhesion receptors (RECEPTORS, LEUKOCYTE ADHESION), and the VERY LATE ANTIGEN RECEPTORS. Each family contains a common beta-subunit (INTEGRIN BETA CHAINS) combined with one or more distinct alpha-subunits (INTEGRIN ALPHA CHAINS). These receptors participate in cell-matrix and cell-cell adhesion in many physiologically important processes, including embryological development; HEMOSTASIS; THROMBOSIS; WOUND HEALING; immune and nonimmune defense mechanisms; and oncogenic transformation.Receptors, Lipoprotein: Cell surface proteins that bind lipoproteins with high affinity. Lipoprotein receptors in the liver and peripheral tissues mediate the regulation of plasma and cellular cholesterol metabolism and concentration. The receptors generally recognize the apolipoproteins of the lipoprotein complex, and binding is often a trigger for endocytosis.Cholesterol: The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils.Cells, Cultured: Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.Cell Line: Established cell cultures that have the potential to propagate indefinitely.TriglyceridesApolipoproteins: Protein components on the surface of LIPOPROTEINS. They form a layer surrounding the hydrophobic lipid core. There are several classes of apolipoproteins with each playing a different role in lipid transport and LIPID METABOLISM. These proteins are synthesized mainly in the LIVER and the INTESTINES.Apolipoproteins B: Major structural proteins of triacylglycerol-rich LIPOPROTEINS. There are two forms, apolipoprotein B-100 and apolipoprotein B-48, both derived from a single gene. ApoB-100 expressed in the liver is found in low-density lipoproteins (LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL). ApoB-48 expressed in the intestine is found in CHYLOMICRONS. They are important in the biosynthesis, transport, and metabolism of triacylglycerol-rich lipoproteins. Plasma Apo-B levels are high in atherosclerotic patients but non-detectable in ABETALIPOPROTEINEMIA.Protein Binding: The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments.Lipoproteins, HDL3: Intermediate-density subclass of the high-density lipoproteins, with particle sizes between 7 to 8 nm. As the larger lighter HDL2 lipoprotein, HDL3 lipoprotein is lipid-rich.Molecular Sequence Data: Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.Receptors, Cell Surface: Cell surface proteins that bind signalling molecules external to the cell with high affinity and convert this extracellular event into one or more intracellular signals that alter the behavior of the target cell (From Alberts, Molecular Biology of the Cell, 2nd ed, pp693-5). Cell surface receptors, unlike enzymes, do not chemically alter their ligands.Lipoproteins, IDL: A mixture of very-low-density lipoproteins (VLDL), particularly the triglyceride-poor VLDL, with slow diffuse electrophoretic mobilities in the beta and alpha2 regions which are similar to that of beta-lipoproteins (LDL) or alpha-lipoproteins (HDL). They can be intermediate (remnant) lipoproteins in the de-lipidation process, or remnants of mutant CHYLOMICRONS and VERY-LOW-DENSITY LIPOPROTEINS which cannot be metabolized completely as seen in FAMILIAL DYSBETALIPOPROTEINEMIA.Receptors, LDL: Receptors on the plasma membrane of nonhepatic cells that specifically bind LDL. The receptors are localized in specialized regions called coated pits. Hypercholesteremia is caused by an allelic genetic defect of three types: 1, receptors do not bind to LDL; 2, there is reduced binding of LDL; and 3, there is normal binding but no internalization of LDL. In consequence, entry of cholesterol esters into the cell is impaired and the intracellular feedback by cholesterol on 3-hydroxy-3-methylglutaryl CoA reductase is lacking.Cell Adhesion: Adherence of cells to surfaces or to other cells.Mice, Inbred C57BLRNA, Messenger: RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.Lipoproteins, HDL2: Low-density subclass of the high-density lipoproteins, with particle sizes between 8 to 13 nm.Amino Acid Sequence: The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.Cholesterol, HDL: Cholesterol which is contained in or bound to high-density lipoproteins (HDL), including CHOLESTEROL ESTERS and free cholesterol.Ligands: A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed)Lipids: A generic term for fats and lipoids, the alcohol-ether-soluble constituents of protoplasm, which are insoluble in water. They comprise the fats, fatty oils, essential oils, waxes, phospholipids, glycolipids, sulfolipids, aminolipids, chromolipids (lipochromes), and fatty acids. (Grant & Hackh's Chemical Dictionary, 5th ed)Signal Transduction: The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.Cholesterol, LDL: Cholesterol which is contained in or bound to low density lipoproteins (LDL), including CHOLESTEROL ESTERS and free cholesterol.Antibodies, Monoclonal: Antibodies produced by a single clone of cells.Reverse Transcriptase Polymerase Chain Reaction: A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols.Cholesterol Esters: Fatty acid esters of cholesterol which constitute about two-thirds of the cholesterol in the plasma. The accumulation of cholesterol esters in the arterial intima is a characteristic feature of atherosclerosis.Apolipoproteins E: A class of protein components which can be found in several lipoproteins including HIGH-DENSITY LIPOPROTEINS; VERY-LOW-DENSITY LIPOPROTEINS; and CHYLOMICRONS. Synthesized in most organs, Apo E is important in the global transport of lipids and cholesterol throughout the body. Apo E is also a ligand for LDL receptors (RECEPTORS, LDL) that mediates the binding, internalization, and catabolism of lipoprotein particles in cells. There are several allelic isoforms (such as E2, E3, and E4). Deficiency or defects in Apo E are causes of HYPERLIPOPROTEINEMIA TYPE III.Chylomicrons: A class of lipoproteins that carry dietary CHOLESTEROL and TRIGLYCERIDES from the SMALL INTESTINE to the tissues. Their density (0.93-1.006 g/ml) is the same as that of VERY-LOW-DENSITY LIPOPROTEINS.Low Density Lipoprotein Receptor-Related Protein-1: A LDL-receptor related protein involved in clearance of chylomicron remnants and of activated ALPHA-MACROGLOBULINS from plasma.Apolipoproteins A: Structural proteins of the alpha-lipoproteins (HIGH DENSITY LIPOPROTEINS), including APOLIPOPROTEIN A-I and APOLIPOPROTEIN A-II. They can modulate the activity of LECITHIN CHOLESTEROL ACYLTRANSFERASE. These apolipoproteins are low in atherosclerotic patients. They are either absent or present in extremely low plasma concentration in TANGIER DISEASE.Apolipoprotein B-100: A 513-kDa protein synthesized in the LIVER. It serves as the major structural protein of low-density lipoproteins (LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL). It is the ligand for the LDL receptor (RECEPTORS, LDL) that promotes cellular binding and internalization of LDL particles.Hyperlipidemias: Conditions with excess LIPIDS in the blood.Cholesterol, VLDL: Cholesterol which is contained in or bound to very low density lipoproteins (VLDL). High circulating levels of VLDL cholesterol are found in HYPERLIPOPROTEINEMIA TYPE IIB. The cholesterol on the VLDL is eventually delivered by LOW-DENSITY LIPOPROTEINS to the tissues after the catabolism of VLDL to INTERMEDIATE-DENSITY LIPOPROTEINS, then to LDL.Ultracentrifugation: Centrifugation with a centrifuge that develops centrifugal fields of more than 100,000 times gravity. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)Arteriosclerosis: Thickening and loss of elasticity of the walls of ARTERIES of all sizes. There are many forms classified by the types of lesions and arteries involved, such as ATHEROSCLEROSIS with fatty lesions in the ARTERIAL INTIMA of medium and large muscular arteries.Apolipoproteins C: A group of apolipoproteins that can readily exchange among the various classes of lipoproteins (HDL; VLDL; CHYLOMICRONS). After lipolysis of TRIGLYCERIDES on VLDL and chylomicrons, Apo-C proteins are normally transferred to HDL. The subtypes can modulate remnant binding to receptors, LECITHIN CHOLESTEROL ACYLTRANSFERASE, or LIPOPROTEIN LIPASE.Hypercholesterolemia: A condition with abnormally high levels of CHOLESTEROL in the blood. It is defined as a cholesterol value exceeding the 95th percentile for the population.Liver: A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances.Lipase: An enzyme of the hydrolase class that catalyzes the reaction of triacylglycerol and water to yield diacylglycerol and a fatty acid anion. It is produced by glands on the tongue and by the pancreas and initiates the digestion of dietary fats. (From Dorland, 27th ed) EC 188.8.131.52.Apolipoprotein B-48: A 241-kDa protein synthesized only in the INTESTINES. It serves as a structural protein of CHYLOMICRONS. Its exclusive association with chylomicron particles provides an indicator of intestinally derived lipoproteins in circulation. Apo B-48 is a shortened form of apo B-100 and lacks the LDL-receptor region.Apolipoprotein A-II: The second most abundant protein component of HIGH DENSITY LIPOPROTEINS or HDL. It has a high lipid affinity and is known to displace APOLIPOPROTEIN A-I from HDL particles and generates a stable HDL complex. ApoA-II can modulate the activation of LECITHIN CHOLESTEROL ACYLTRANSFERASE in the presence of APOLIPOPROTEIN A-I, thus affecting HDL metabolism.Cholesterol, Dietary: Cholesterol present in food, especially in animal products.Hypertriglyceridemia: A condition of elevated levels of TRIGLYCERIDES in the blood.Lipid Metabolism: Physiological processes in biosynthesis (anabolism) and degradation (catabolism) of LIPIDS.Hyperlipoproteinemias: Conditions with abnormally elevated levels of LIPOPROTEINS in the blood. They may be inherited, acquired, primary, or secondary. Hyperlipoproteinemias are classified according to the pattern of lipoproteins on electrophoresis or ultracentrifugation.Hyperlipoproteinemia Type II: A group of familial disorders characterized by elevated circulating cholesterol contained in either LOW-DENSITY LIPOPROTEINS alone or also in VERY-LOW-DENSITY LIPOPROTEINS (pre-beta lipoproteins).Apolipoprotein C-II: A 9-kDa protein component of VERY-LOW-DENSITY LIPOPROTEINS. It contains a cofactor for LIPOPROTEIN LIPASE and activates several triacylglycerol lipases. The association of Apo C-II with plasma CHYLOMICRONS; VLDL, and HIGH-DENSITY LIPOPROTEINS is reversible and changes rapidly as a function of triglyceride metabolism. Clinically, Apo C-II deficiency is similar to lipoprotein lipase deficiency (HYPERLIPOPROTEINEMIA TYPE I) and is therefore called hyperlipoproteinemia type IB.Apolipoprotein C-III: A 9-kDa protein component of VERY-LOW-DENSITY LIPOPROTEINS and CHYLOMICRON REMNANTS. Apo C-III, synthesized in the liver, is an inhibitor of LIPOPROTEIN LIPASE. Apo C-III modulates the binding of chylomicron remnants and VLDL to receptors (RECEPTORS, LDL) thus decreases the uptake of triglyceride-rich particles by the liver cells and subsequent degradation. The normal Apo C-III is glycosylated. There are several polymorphic forms with varying amounts of SIALIC ACID (Apo C-III-0, Apo C-III-1, and Apo C-III-2).Cholesterol Ester Transfer Proteins: Proteins that bind to and transfer CHOLESTEROL ESTERS between LIPOPROTEINS such as LOW-DENSITY LIPOPROTEINS and HIGH-DENSITY LIPOPROTEINS.Phospholipids: Lipids containing one or more phosphate groups, particularly those derived from either glycerol (phosphoglycerides see GLYCEROPHOSPHOLIPIDS) or sphingosine (SPHINGOLIPIDS). They are polar lipids that are of great importance for the structure and function of cell membranes and are the most abundant of membrane lipids, although not stored in large amounts in the system.Phosphatidylcholine-Sterol O-Acyltransferase: An enzyme secreted from the liver into the plasma of many mammalian species. It catalyzes the esterification of the hydroxyl group of lipoprotein cholesterol by the transfer of a fatty acid from the C-2 position of lecithin. In familial lecithin:cholesterol acyltransferase deficiency disease, the absence of the enzyme results in an excess of unesterified cholesterol in plasma. EC 184.108.40.206.Atherosclerosis: A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.Apoprotein(a): A large and highly glycosylated protein constituent of LIPOPROTEIN (A). It has very little affinity for lipids but forms disulfide-linkage to APOLIPOPROTEIN B-100. Apoprotein(a) has SERINE PROTEINASE activity and can be of varying sizes from 400- to 800-kDa. It is homologous to PLASMINOGEN and is known to modulate THROMBOSIS and FIBRINOLYSIS.Dietary Fats: Fats present in food, especially in animal products such as meat, meat products, butter, ghee. They are present in lower amounts in nuts, seeds, and avocados.Scavenger Receptors, Class B: A family of scavenger receptors that are predominately localized to CAVEOLAE of the PLASMA MEMBRANE and bind HIGH DENSITY LIPOPROTEINS.Receptors, Scavenger: A large group of structurally diverse cell surface receptors that mediate endocytic uptake of modified LIPOPROTEINS. Scavenger receptors are expressed by MYELOID CELLS and some ENDOTHELIAL CELLS, and were originally characterized based on their ability to bind acetylated LOW-DENSITY LIPOPROTEINS. They can also bind a variety of other polyanionic ligand. Certain scavenger receptors can internalize micro-organisms as well as apoptotic cells.Kinetics: The rate dynamics in chemical or physical systems.Particle Size: Relating to the size of solids.Hyperlipoproteinemia Type I: An inherited condition due to a deficiency of either LIPOPROTEIN LIPASE or APOLIPOPROTEIN C-II (a lipase-activating protein). The lack of lipase activities results in inability to remove CHYLOMICRONS and TRIGLYCERIDES from the blood which has a creamy top layer after standing.Hyperlipoproteinemia Type IV: A hypertriglyceridemia disorder, often with autosomal dominant inheritance. It is characterized by the persistent elevations of plasma TRIGLYCERIDES, endogenously synthesized and contained predominantly in VERY-LOW-DENSITY LIPOPROTEINS (pre-beta lipoproteins). In contrast, the plasma CHOLESTEROL and PHOSPHOLIPIDS usually remain within normal limits.Oxidation-Reduction: A chemical reaction in which an electron is transferred from one molecule to another. The electron-donating molecule is the reducing agent or reductant; the electron-accepting molecule is the oxidizing agent or oxidant. Reducing and oxidizing agents function as conjugate reductant-oxidant pairs or redox pairs (Lehninger, Principles of Biochemistry, 1982, p471).Carrier Proteins: Transport proteins that carry specific substances in the blood or across cell membranes.Anticholesteremic Agents: Substances used to lower plasma CHOLESTEROL levels.Triolein: (Z)-9-Octadecenoic acid 1,2,3-propanetriyl ester.Macrophages: The relatively long-lived phagocytic cell of mammalian tissues that are derived from blood MONOCYTES. Main types are PERITONEAL MACROPHAGES; ALVEOLAR MACROPHAGES; HISTIOCYTES; KUPFFER CELLS of the liver; and OSTEOCLASTS. They may further differentiate within chronic inflammatory lesions to EPITHELIOID CELLS or may fuse to form FOREIGN BODY GIANT CELLS or LANGHANS GIANT CELLS. (from The Dictionary of Cell Biology, Lackie and Dow, 3rd ed.)Hypolipidemic Agents: Substances that lower the levels of certain LIPIDS in the BLOOD. They are used to treat HYPERLIPIDEMIAS.Heparin: A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts.Foam Cells: Lipid-laden macrophages originating from monocytes or from smooth muscle cells.Antigens, CD36: Leukocyte differentiation antigens and major platelet membrane glycoproteins present on MONOCYTES; ENDOTHELIAL CELLS; PLATELETS; and mammary EPITHELIAL CELLS. They play major roles in CELL ADHESION; SIGNAL TRANSDUCTION; and regulation of angiogenesis. CD36 is a receptor for THROMBOSPONDINS and can act as a scavenger receptor that recognizes and transports oxidized LIPOPROTEINS and FATTY ACIDS.Scavenger Receptors, Class E: A class of oxidized LDL receptors that contain LECTIN-like extracellular domains.Lipolysis: The metabolic process of breaking down LIPIDS to release FREE FATTY ACIDS, the major oxidative fuel for the body. Lipolysis may involve dietary lipids in the DIGESTIVE TRACT, circulating lipids in the BLOOD, and stored lipids in the ADIPOSE TISSUE or the LIVER. A number of enzymes are involved in such lipid hydrolysis, such as LIPASE and LIPOPROTEIN LIPASE from various tissues.Hypolipoproteinemias: Conditions with abnormally low levels of LIPOPROTEINS in the blood. This may involve any of the lipoprotein subclasses, including ALPHA-LIPOPROTEINS (high-density lipoproteins); BETA-LIPOPROTEINS (low-density lipoproteins); and PREBETA-LIPOPROTEINS (very-low-density lipoproteins).Dyslipidemias: Abnormalities in the serum levels of LIPIDS, including overproduction or deficiency. Abnormal serum lipid profiles may include high total CHOLESTEROL, high TRIGLYCERIDES, low HIGH DENSITY LIPOPROTEIN CHOLESTEROL, and elevated LOW DENSITY LIPOPROTEIN CHOLESTEROL.Fatty Acids: Organic, monobasic acids derived from hydrocarbons by the equivalent of oxidation of a methyl group to an alcohol, aldehyde, and then acid. Fatty acids are saturated and unsaturated (FATTY ACIDS, UNSATURATED). (Grant & Hackh's Chemical Dictionary, 5th ed)Electrophoresis, Polyacrylamide Gel: Electrophoresis in which a polyacrylamide gel is used as the diffusion medium.Hyperlipoproteinemia Type III: An autosomal recessively inherited disorder characterized by the accumulation of intermediate-density lipoprotein (IDL or broad-beta-lipoprotein). IDL has a CHOLESTEROL to TRIGLYCERIDES ratio greater than that of VERY-LOW-DENSITY LIPOPROTEINS. This disorder is due to mutation of APOLIPOPROTEINS E, a receptor-binding component of VLDL and CHYLOMICRONS, resulting in their reduced clearance and high plasma levels of both cholesterol and triglycerides.Abetalipoproteinemia: An autosomal recessive disorder of lipid metabolism. It is caused by mutation of the microsomal triglyceride transfer protein that catalyzes the transport of lipids (TRIGLYCERIDES; CHOLESTEROL ESTERS; PHOSPHOLIPIDS) and is required in the secretion of BETA-LIPOPROTEINS (low density lipoproteins or LDL). Features include defective intestinal lipid absorption, very low serum cholesterol level, and near absent LDL.Rabbits: The species Oryctolagus cuniculus, in the family Leporidae, order LAGOMORPHA. Rabbits are born in burrows, furless, and with eyes and ears closed. In contrast with HARES, rabbits have 22 chromosome pairs.Esterification: The process of converting an acid into an alkyl or aryl derivative. Most frequently the process consists of the reaction of an acid with an alcohol in the presence of a trace of mineral acid as catalyst or the reaction of an acyl chloride with an alcohol. Esterification can also be accomplished by enzymatic processes.Apoproteins: The protein components of a number of complexes, such as enzymes (APOENZYMES), ferritin (APOFERRITINS), or lipoproteins (APOLIPOPROTEINS).Risk Factors: An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.Hydroxymethylglutaryl-CoA Reductase Inhibitors: Compounds that inhibit HMG-CoA reductases. They have been shown to directly lower cholesterol synthesis.Apolipoprotein C-I: A 6.6-kDa protein component of VERY-LOW-DENSITY LIPOPROTEINS; INTERMEDIATE-DENSITY LIPOPROTEINS; and HIGH-DENSITY LIPOPROTEINS. Apo C-I displaces APO E from lipoproteins, modulate their binding to receptors (RECEPTORS, LDL), and thereby decrease their clearance from plasma. Elevated Apo C-I levels are associated with HYPERLIPOPROTEINEMIA and ATHEROSCLEROSIS.Apolipoprotein E3: A 34-kDa glycosylated protein. A major and most common isoform of apolipoprotein E. Therefore, it is also known as apolipoprotein E (ApoE). In human, Apo E3 is a 299-amino acid protein with a cysteine at the 112 and an arginine at the 158 position. It is involved with the transport of TRIGLYCERIDES; PHOSPHOLIPIDS; CHOLESTEROL; and CHOLESTERYL ESTERS in and out of the cells.Biological Transport: The movement of materials (including biochemical substances and drugs) through a biological system at the cellular level. The transport can be across cell membranes and epithelial layers. It also can occur within intracellular compartments and extracellular compartments.Lymph: The interstitial fluid that is in the LYMPHATIC SYSTEM.Aryldialkylphosphatase: An enzyme which catalyzes the hydrolysis of an aryl-dialkyl phosphate to form dialkyl phosphate and an aryl alcohol. It can hydrolyze a broad spectrum of organophosphate substrates and a number of aromatic carboxylic acid esters. It may also mediate an enzymatic protection of LOW DENSITY LIPOPROTEINS against oxidative modification and the consequent series of events leading to ATHEROMA formation. The enzyme was previously regarded to be identical with Arylesterase (EC 220.127.116.11).LDL-Receptor Related Proteins: A family of proteins that share sequence similarity with the low density lipoprotein receptor (RECEPTORS, LDL).Hyperlipidemia, Familial Combined: A type of familial lipid metabolism disorder characterized by a variable pattern of elevated plasma CHOLESTEROL and/or TRIGLYCERIDES. Multiple genes on different chromosomes may be involved, such as the major late transcription factor (UPSTREAM STIMULATORY FACTORS) on CHROMOSOME 1.Coronary Disease: An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.Hydroxymethylglutaryl CoA Reductases: Enzymes that catalyze the reversible reduction of alpha-carboxyl group of 3-hydroxy-3-methylglutaryl-coenzyme A to yield MEVALONIC ACID.Aorta: The main trunk of the systemic arteries.Oleic Acid: An unsaturated fatty acid that is the most widely distributed and abundant fatty acid in nature. It is used commercially in the preparation of oleates and lotions, and as a pharmaceutical solvent. (Stedman, 26th ed)Sterol O-Acyltransferase: An enzyme that catalyzes the formation of cholesterol esters by the direct transfer of the fatty acid group from a fatty acyl CoA derivative. This enzyme has been found in the adrenal gland, gonads, liver, intestinal mucosa, and aorta of many mammalian species. EC 18.104.22.168.Electrophoresis, Agar Gel: Electrophoresis in which agar or agarose gel is used as the diffusion medium.Oleic Acids: A group of fatty acids that contain 18 carbon atoms and a double bond at the omega 9 carbon.Fasting: Abstaining from all food.ATP Binding Cassette Transporter 1: A superfamily of large integral ATP-binding cassette membrane proteins whose expression pattern is consistent with a role in lipid (cholesterol) efflux. It is implicated in TANGIER DISEASE characterized by accumulation of cholesteryl ester in various tissues.Phosphatidylcholines: Derivatives of phosphatidic acids in which the phosphoric acid is bound in ester linkage to a choline moiety. Complete hydrolysis yields 1 mole of glycerol, phosphoric acid and choline and 2 moles of fatty acids.Lecithin Acyltransferase Deficiency: An autosomal recessively inherited disorder caused by mutation of LECITHIN CHOLESTEROL ACYLTRANSFERASE that facilitates the esterification of lipoprotein cholesterol and subsequent removal from peripheral tissues to the liver. This defect results in low HDL-cholesterol level in blood and accumulation of free cholesterol in tissue leading to a triad of CORNEAL OPACITY, hemolytic anemia (ANEMIA, HEMOLYTIC), and PROTEINURIA.Time Factors: Elements of limited time intervals, contributing to particular results or situations.Adipose Tissue: Specialized connective tissue composed of fat cells (ADIPOCYTES). It is the site of stored FATS, usually in the form of TRIGLYCERIDES. In mammals, there are two types of adipose tissue, the WHITE FAT and the BROWN FAT. Their relative distributions vary in different species with most adipose tissue being white.Tangier Disease: An autosomal recessively inherited disorder caused by mutation of ATP-BINDING CASSETTE TRANSPORTERS involved in cellular cholesterol removal (reverse-cholesterol transport). It is characterized by near absence of ALPHA-LIPOPROTEINS (high-density lipoproteins) in blood. The massive tissue deposition of cholesterol esters results in HEPATOMEGALY; SPLENOMEGALY; RETINITIS PIGMENTOSA; large orange tonsils; and often sensory POLYNEUROPATHY. The disorder was first found among inhabitants of Tangier Island in the Chesapeake Bay, MD.Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).Postprandial Period: The time frame after a meal or FOOD INTAKE.Diet, Atherogenic: A diet that contributes to the development and acceleration of ATHEROGENESIS.Lovastatin: A fungal metabolite isolated from cultures of Aspergillus terreus. The compound is a potent anticholesteremic agent. It inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It also stimulates the production of low-density lipoprotein receptors in the liver.Phospholipid Transfer Proteins: A ubiquitous family of proteins that transport PHOSPHOLIPIDS such as PHOSPHATIDYLINOSITOL and PHOSPHATIDYLCHOLINE between membranes. They play an important role in phospholipid metabolism during vesicular transport and SIGNAL TRANSDUCTION.Blood Protein Electrophoresis: Electrophoresis applied to BLOOD PROTEINS.LDL-Receptor Related Protein-Associated Protein: A membrane protein found in the rough endoplasm reticulum (ENDOPLASMIC RETICULUM, ROUGH) that binds to LDL-RECEPTOR RELATED PROTEINS. It may function to prevent ligand binding of receptors during protein processing events within endosomal compartments.High-Density Lipoproteins, Pre-beta: A highly dense subclass of the high-density lipoproteins, with particle sizes below 7 nm. They are also known as nascent HDL, composed of a few APOLIPOPROTEIN A-I molecules which are complexed with PHOSPHOLIPIDS. The lipid-poor pre-beta-HDL particles serve as progenitors of HDL3 and then HDL2 after absorption of free cholesterol from cell membranes, cholesterol esterification, and acquisition of apolipoproteins A-II, Cs, and E. Pre-beta-HDL initiate the reverse cholesterol transport process from cells to liver.Bacterial Outer Membrane Proteins: Proteins isolated from the outer membrane of Gram-negative bacteria.Lipid Peroxidation: Peroxidase catalyzed oxidation of lipids using hydrogen peroxide as an electron acceptor.Apolipoprotein E2: One of three major isoforms of apolipoprotein E. In humans, Apo E2 differs from APOLIPOPROTEIN E3 at one residue 158 where arginine is replaced by cysteine (R158--C). In contrast to Apo E3, Apo E2 displays extremely low binding affinity for LDL receptors (RECEPTORS, LDL) which mediate the internalization and catabolism of lipoprotein particles in liver cells. ApoE2 allelic homozygosity is associated with HYPERLIPOPROTEINEMIA TYPE III.Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.Mice, Knockout: Strains of mice in which certain GENES of their GENOMES have been disrupted, or "knocked-out". To produce knockouts, using RECOMBINANT DNA technology, the normal DNA sequence of the gene being studied is altered to prevent synthesis of a normal gene product. Cloned cells in which this DNA alteration is successful are then injected into mouse EMBRYOS to produce chimeric mice. The chimeric mice are then bred to yield a strain in which all the cells of the mouse contain the disrupted gene. Knockout mice are used as EXPERIMENTAL ANIMAL MODELS for diseases (DISEASE MODELS, ANIMAL) and to clarify the functions of the genes.Vitamin E: A generic descriptor for all TOCOPHEROLS and TOCOTRIENOLS that exhibit ALPHA-TOCOPHEROL activity. By virtue of the phenolic hydrogen on the 2H-1-benzopyran-6-ol nucleus, these compounds exhibit varying degree of antioxidant activity, depending on the site and number of methyl groups and the type of ISOPRENOIDS.Microscopy, Electron: Microscopy using an electron beam, instead of light, to visualize the sample, thereby allowing much greater magnification. The interactions of ELECTRONS with specimens are used to provide information about the fine structure of that specimen. In TRANSMISSION ELECTRON MICROSCOPY the reactions of the electrons that are transmitted through the specimen are imaged. In SCANNING ELECTRON MICROSCOPY an electron beam falls at a non-normal angle on the specimen and the image is derived from the reactions occurring above the plane of the specimen.Lysophosphatidylcholines: Derivatives of PHOSPHATIDYLCHOLINES obtained by their partial hydrolysis which removes one of the fatty acid moieties.Iodine Radioisotopes: Unstable isotopes of iodine that decay or disintegrate emitting radiation. I atoms with atomic weights 117-139, except I 127, are radioactive iodine isotopes.Emulsions: Colloids formed by the combination of two immiscible liquids such as oil and water. Lipid-in-water emulsions are usually liquid, like milk or lotion. Water-in-lipid emulsions tend to be creams. The formation of emulsions may be aided by amphiphatic molecules that surround one component of the system to form MICELLES.Receptors, Oxidized LDL: A group of cell-surface receptors for oxidatively modified LOW-DENSITY LIPOPROTEINS. The group includes certain SCAVENGER RECEPTORS that contribute to the pathogenesis of ATHEROSCLEROSIS by uptake of oxidized LDL.Chromatography, Gel: Chromatography on non-ionic gels without regard to the mechanism of solute discrimination.Reference Values: The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality.Glycoproteins: Conjugated protein-carbohydrate compounds including mucins, mucoid, and amyloid glycoproteins.Biological Markers: Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, environmental exposure and its effects, disease diagnosis, metabolic processes, substance abuse, pregnancy, cell line development, epidemiologic studies, etc.Chemical Precipitation: The formation of a solid in a solution as a result of a chemical reaction or the aggregation of soluble substances into complexes large enough to fall out of solution.Heptanoic Acids: 7-carbon saturated monocarboxylic acids.Cricetinae: A subfamily in the family MURIDAE, comprising the hamsters. Four of the more common genera are Cricetus, CRICETULUS; MESOCRICETUS; and PHODOPUS.1-Alkyl-2-acetylglycerophosphocholine Esterase: A lipoprotein-associated PHOSPHOLIPASE A2 which modulates the action of PLATELET ACTIVATING FACTOR by hydrolyzing the SN-2 ester bond to yield the biologically inactive lyso-platelet-activating factor. It has specificity for phospholipid substrates with short-chain residues at the SN-2 position, but inactive against long-chain phospholipids. Deficiency in this enzyme is associated with many diseases including ASTHMA, and HYPERCHOLESTEROLEMIA.Molecular Weight: The sum of the weight of all the atoms in a molecule.Endothelium, Vascular: Single pavement layer of cells which line the luminal surface of the entire vascular system and regulate the transport of macromolecules and blood components.Fatty Acids, Nonesterified: FATTY ACIDS found in the plasma that are complexed with SERUM ALBUMIN for transport. These fatty acids are not in glycerol ester form.Fibroblasts: Connective tissue cells which secrete an extracellular matrix rich in collagen and other macromolecules.Cell Membrane: The lipid- and protein-containing, selectively permeable membrane that surrounds the cytoplasm in prokaryotic and eukaryotic cells.Membrane Proteins: Proteins which are found in membranes including cellular and intracellular membranes. They consist of two types, peripheral and integral proteins. They include most membrane-associated enzymes, antigenic proteins, transport proteins, and drug, hormone, and lectin receptors.Egg Yolk: Cytoplasm stored in an egg that contains nutritional reserves for the developing embryo. It is rich in polysaccharides, lipids, and proteins.Base Sequence: The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.alpha-Macroglobulins: Glycoproteins with a molecular weight of approximately 620,000 to 680,000. Precipitation by electrophoresis is in the alpha region. They include alpha 1-macroglobulins and alpha 2-macroglobulins. These proteins exhibit trypsin-, chymotrypsin-, thrombin-, and plasmin-binding activity and function as hormonal transporters.Centrifugation, Density Gradient: Separation of particles according to density by employing a gradient of varying densities. At equilibrium each particle settles in the gradient at a point equal to its density. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.ATP-Binding Cassette Transporters: A family of MEMBRANE TRANSPORT PROTEINS that require ATP hydrolysis for the transport of substrates across membranes. The protein family derives its name from the ATP-binding domain found on the protein.Blood Glucose: Glucose in blood.Blood Protein DisordersEndocytosis: Cellular uptake of extracellular materials within membrane-limited vacuoles or microvesicles. ENDOSOMES play a central role in endocytosis.Coronary Artery Disease: Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.Cattle: Domesticated bovine animals of the genus Bos, usually kept on a farm or ranch and used for the production of meat or dairy products or for heavy labor.Rats, Inbred Strains: Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations or by parent x offspring matings carried out with certain restrictions. This also includes animals with a long history of closed colony breeding.Homozygote: An individual in which both alleles at a given locus are identical.Scavenger Receptors, Class A: A family of scavenger receptors that mediate the influx of LIPIDS into MACROPHAGES and are involved in FOAM CELL formation.Lipoprotein-X: An abnormal lipoprotein present in large amounts in patients with obstructive liver diseases such as INTRAHEPATIC CHOLESTASIS. LP-X derives from the reflux of BILE lipoproteins into the bloodstream. LP-X is a low-density lipoprotein rich in free CHOLESTEROL and PHOSPHOLIPIDS but poor in TRIGLYCERIDES; CHOLESTEROL ESTERS; and protein.Sterols: Steroids with a hydroxyl group at C-3 and most of the skeleton of cholestane. Additional carbon atoms may be present in the side chain. (IUPAC Steroid Nomenclature, 1987)Lipid Peroxides: Peroxides produced in the presence of a free radical by the oxidation of unsaturated fatty acids in the cell in the presence of molecular oxygen. The formation of lipid peroxides results in the destruction of the original lipid leading to the loss of integrity of the membranes. They therefore cause a variety of toxic effects in vivo and their formation is considered a pathological process in biological systems. Their formation can be inhibited by antioxidants, such as vitamin E, structural separation or low oxygen tension.Simvastatin: A derivative of LOVASTATIN and potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It may also interfere with steroid hormone production. Due to the induction of hepatic LDL RECEPTORS, it increases breakdown of LDL CHOLESTEROL.Low Density Lipoprotein Receptor-Related Protein-5: LDL-receptor related protein that combines with FRIZZLED RECEPTORS at the cell surface to form receptors that bind WNT PROTEINS. The protein plays an important role in the WNT SIGNALING PATHWAY in OSTEOBLASTS and during EMBRYONIC DEVELOPMENT.Hyperlipoproteinemia Type V: A severe type of hyperlipidemia, sometimes familial, that is characterized by the elevation of both plasma CHYLOMICRONS and TRIGLYCERIDES contained in VERY-LOW-DENSITY LIPOPROTEINS. Type V hyperlipoproteinemia is often associated with DIABETES MELLITUS and is not caused by reduced LIPOPROTEIN LIPASE activity as in HYPERLIPOPROTEINEMIA TYPE I .Bacterial Proteins: Proteins found in any species of bacterium.Copper: A heavy metal trace element with the atomic symbol Cu, atomic number 29, and atomic weight 63.55.Plant Oils: Oils derived from plants or plant products.Immunoelectrophoresis: A technique that combines protein electrophoresis and double immunodiffusion. In this procedure proteins are first separated by gel electrophoresis (usually agarose), then made visible by immunodiffusion of specific antibodies. A distinct elliptical precipitin arc results for each protein detectable by the antisera.Fat Emulsions, Intravenous: Emulsions of fats or lipids used primarily in parenteral feeding.Monocytes: Large, phagocytic mononuclear leukocytes produced in the vertebrate BONE MARROW and released into the BLOOD; contain a large, oval or somewhat indented nucleus surrounded by voluminous cytoplasm and numerous organelles.Phenotype: The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment.Mutation: Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.Copper Sulfate: A sulfate salt of copper. It is a potent emetic and is used as an antidote for poisoning by phosphorus. It also can be used to prevent the growth of algae.Insulin: A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1).Antioxidants: Naturally occurring or synthetic substances that inhibit or retard the oxidation of a substance to which it is added. They counteract the harmful and damaging effects of oxidation in animal tissues.Binding, Competitive: The interaction of two or more substrates or ligands with the same binding site. The displacement of one by the other is used in quantitative and selective affinity measurements.Obesity: A status with BODY WEIGHT that is grossly above the acceptable or desirable weight, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.Diet: Regular course of eating and drinking adopted by a person or animal.Hydroxycholesterols: Cholesterol which is substituted by a hydroxy group in any position.Immunodiffusion: Technique involving the diffusion of antigen or antibody through a semisolid medium, usually agar or agarose gel, with the result being a precipitin reaction.Pravastatin: An antilipemic fungal metabolite isolated from cultures of Nocardia autotrophica. It acts as a competitive inhibitor of HMG CoA reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES).Xanthomatosis: A condition marked by the development of widespread xanthomas, yellow tumor-like structures filled with lipid deposits. Xanthomas can be found in a variety of tissues including the SKIN; TENDONS; joints of KNEES and ELBOWS. Xanthomatosis is associated with disturbance of LIPID METABOLISM and formation of FOAM CELLS.Body Mass Index: An indicator of body density as determined by the relationship of BODY WEIGHT to BODY HEIGHT. BMI=weight (kg)/height squared (m2). BMI correlates with body fat (ADIPOSE TISSUE). Their relationship varies with age and gender. For adults, BMI falls into these categories: below 18.5 (underweight); 18.5-24.9 (normal); 25.0-29.9 (overweight); 30.0 and above (obese). (National Center for Health Statistics, Centers for Disease Control and Prevention)Pyrroles: Azoles of one NITROGEN and two double bonds that have aromatic chemical properties.Phosphotungstic Acid: Tungsten hydroxide oxide phosphate. A white or slightly yellowish-green, slightly efflorescent crystal or crystalline powder. It is used as a reagent for alkaloids and many other nitrogen bases, for phenols, albumin, peptone, amino acids, uric acid, urea, blood, and carbohydrates. (From Merck Index, 11th ed)Heterozygote: An individual having different alleles at one or more loci regarding a specific character.CHO Cells: CELL LINE derived from the ovary of the Chinese hamster, Cricetulus griseus (CRICETULUS). The species is a favorite for cytogenetic studies because of its small chromosome number. The cell line has provided model systems for the study of genetic alterations in cultured mammalian cells.Chylomicron Remnants: Metabolic products of chylomicron particles in which TRIGLYCERIDES have been selectively removed by the LIPOPROTEIN LIPASE. These remnants carry dietary lipids in the blood and are cholesterol-rich. Their interactions with MACROPHAGES; ENDOTHELIAL CELLS; and SMOOTH MUSCLE CELLS in the artery wall can lead to ATHEROSCLEROSIS.Recombinant Proteins: Proteins prepared by recombinant DNA technology.Chromatography, Affinity: A chromatographic technique that utilizes the ability of biological molecules to bind to certain ligands specifically and reversibly. It is used in protein biochemistry. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)Heparin Lyase: An enzyme of the isomerase class that catalyzes the eliminative cleavage of polysaccharides containing 1,4-linked D-glucuronate or L-iduronate residues and 1,4-alpha-linked 2-sulfoamino-2-deoxy-6-sulfo-D-glucose residues to give oligosaccharides with terminal 4-deoxy-alpha-D-gluc-4-enuronosyl groups at their non-reducing ends. (From Enzyme Nomenclature, 1992) EC 22.214.171.124.Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.AzetidinesThiobarbituric Acid Reactive Substances: Low-molecular-weight end products, probably malondialdehyde, that are formed during the decomposition of lipid peroxidation products. These compounds react with thiobarbituric acid to form a fluorescent red adduct.Macrophages, Peritoneal: Mononuclear phagocytes derived from bone marrow precursors but resident in the peritoneum.Low Density Lipoprotein Receptor-Related Protein-6: An LDL-receptor related protein that combines with cell surface FRIZZLED RECEPTORS to form WNT PROTEIN-binding receptors. The protein plays an important role in the WNT SIGNALING PATHWAY during EMBRYONIC DEVELOPMENT and in regulation of vascular cell proliferation.Hypobetalipoproteinemias: Conditions with abnormally low levels of BETA-LIPOPROTEINS (low density lipoproteins or LDL) in the blood. It is defined as LDL values equal to or less than the 5th percentile for the population. They include the autosomal dominant form involving mutation of the APOLIPOPROTEINS B gene, and the autosomal recessive form involving mutation of the microsomal triglyceride transfer protein. All are characterized by low LDL and dietary fat malabsorption.Fenofibrate: An antilipemic agent which reduces both CHOLESTEROL and TRIGLYCERIDES in the blood.Metabolic Syndrome X: A cluster of metabolic risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome X include excess ABDOMINAL FAT; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state. (from AHA/NHLBI/ADA Conference Proceedings, Circulation 2004; 109:551-556)
... acts as a lipoprotein-lowering drug through two pathways. In the major pathway, pravastatin inhibits the function ... which are the precursor to low-density lipoproteins (LDL). These reductions increase the number of cellular LDL receptors, thus ... In 2005, Pravachol was the 22nd-highest selling brand-name drug in the United States, with sales totaling $1.3 billion. The U.S ... Pravastatin (marketed as Pravachol or Selektine) is a member of the drug class of statins, used in combination with diet, ...
... ligation of death receptors, and chemotherapy drugs. The main mechanism of trafficking L-SMase to the lysosome is through the ... The lysosomal acidic SMase is considered one of the major candidates for the production of ceramide in the cellular response to ... S-SMases are zinc-dependent, and have been implicated in the metabolism of lipoprotein-bound SM to Ceramide and the aggregation ... Acid SMase has been shown to accelerate atherosclerotic lesion progression through promoting aggreation of lipoproteins to ...
... tissue-specific depletion of the high density lipoprotein receptor scavenger receptor class B type I and altered lipoprotein ... a major scaffolder in brush borders of proximal tubular cells". Kidney Int. 64 (5): 1733-45. doi:10.1046/j.1523-1755.2003.00266 ... "Overexpression of PDZK1 within the 1q12-q22 Amplicon Is Likely To Be Associated with Drug-Resistance Phenotype in Multiple ... Silver DL (2002). "A carboxyl-terminal PDZ-interacting domain of scavenger receptor B, type I is essential for cell surface ...
The very-low-density-lipoprotein receptor (VLDLR) is a transmembrane lipoprotein receptor of the low-density-lipoprotein (LDL) ... "Decreased expression of reelin receptor VLDLR in peripheral lymphocytes of drug-naive schizophrenic patients". Schizophr. Res. ... Despite its major role in cholesterol and fatty acid metabolism, VLDLR is not found in the liver. This phenomenon is mainly ... low density lipoprotein receptor, very low density lipoprotein receptor, and apolipoprotein E receptor-2". Biochim. Biophys. ...
... binds to the receptor for low-density lipoprotein particles (LDL), which typically transport 3,000 to 6,000 fat molecules ... Food and Drug Administration in 2015 for lowering LDL-particle concentrations when statins and other drugs were not ... Giunzioni I, Tavori H, Covarrubias R, Major AS, Ding L, Zhang Y, DeVay RM, Hong L, Fan D, Predazzi IM, Rashid S, Linton MF, ... subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor ...
These drug interactions with fenofibrate are considered major and may need therapy modifications: Bile acid sequestrants (e.g. ... It lowers lipid levels by activating peroxisome proliferator-activated receptor alpha (PPARα). PPARα activates lipoprotein ... Like other fibrates, it reduces both low-density lipoprotein (LDL) and very low density lipoprotein (VLDL) levels, as well as ... Fenofibrate, marketed as Tricor and under several other brand names, is a drug of the fibrate class. It is mainly used to ...
... leaves and their major flavonol quercetin 3-(6-malonylglucoside) attenuate atherosclerotic lesion development in LDL receptor- ... "Small Molecules from Nature Targeting G-Protein Coupled Cannabinoid Receptors: Potential Leads for Drug Discovery and ... Curbing Clots, Sept, 2012 Chang S, Tan C, Frankel EN, Barrett DM (Feb 2000). "Low-density lipoprotein antioxidant activity of ... Rutin treatment showed upregulation of CB1 receptors in mouse brain tissue demonstrating antifatigue activity and CB1 receptor- ...
Albert Einstein College of Medicine
... and cloning of the leptin and leptin receptor genes, has had a major role in the area of understanding human obesity. Allison ... Marc Galanter, M.D. (Class of 1971). Deputy Director of the Division of Alcoholism and Drug Abuse in the Department of ... Einstein researchers demonstrated the association between reduced levels of high-density lipoproteins (HDL), or "good" ... Einstein is a major biomedical and clinical research facility. Faculty members received $157 million in research grants from ...
Thomas C. Südhof
When LDL receptors, found concentrated in the liver, bind specific free blood cholesterol, low-density lipoprotein, they are ... Sterols are a major class of biomolecule and critical for life. Important sterols in humans include cholesterol and steroid ... drug development. 1993 W. Alden Spencer Award from Columbia University (shared with Richard Scheller) 1994 Wilhelm Feldberg ... While a postdoctoral fellow, Südhof cloned the gene for the low-density lipoprotein receptor and, soon after, was able to ...
... apoA-I for HDL receptors) There are two major types of apolipoproteins. Apolipoproteins B form low-density lipoprotein ( ... and various drugs (statins, niacin, and fibric acids). Apo B is an integral apoprotein whereas the others are peripheral ... Lipid transport proteins Ligands for interaction with lipoprotein receptors in tissues ( apoB100 and apoE for LDL-receptors, ... In particular, apoA1 is the major protein component of high-density lipoproteins; apoA4 is thought to act primarily in ...
Uptake via the LDL receptor is not a major pathway of Lp(a) metabolism. The kidney has been identified as playing a role in Lp( ... "The Effects of Tamoxifen on Plasma Lipoprotein(a) Concentrations: Systematic Review and Meta-Analysis". Drugs. 77 (11): 1187- ... Lipoprotein Apolipoprotein Very-low-density lipoprotein Low-density lipoprotein Combined hyperlipidemia GRCh38: Ensembl release ... Lipoprotein(a) was discovered in 1963 by Kåre Berg. The human gene encoding apolipoprotein(a) was cloned in 1987. Lipoprotein(a ...
"Human CD36 is a high affinity receptor for the native lipoproteins HDL, LDL, and VLDL". Journal of Lipid Research. 39 (4): 777- ... of erythrocytes infected with mature forms of the parasite and CD36 has been shown to be a major sequestration receptor on ... including the thiazolidinedione class of anti-diabetic drugs and the vitamin A metabolite 9-cis-retinoic acid respectively. ... The protein itself belongs to the class B scavenger receptor family which includes receptors for selective cholesteryl ester ...
The potential for these contraindications and drug-drug interaction could lead to asystole and cardiac arrest. Certain calcium ... Beta-receptor antagonists do not cause vasodilation, but like L-type calcium channel blockers, they do reduce the heart's ... Vasospasm is the major cause of Prinzmetal's angina. Normally endothelial cells release prostacyclin and nitric oxide (NO) ... This can be done in several ways, the most important being lifestyle modifications-decreasing low-density lipoprotein (LDL), ...
Certain drugs also may be associated with insulin resistance (e.g., glucocorticoids). ... Hotamisligil GS (June 1999). "The role of TNFalpha and TNF receptors in obesity and insulin resistance". Journal of Internal ... High plasma levels of insulin and glucose due to insulin resistance are a major component of the metabolic syndrome. If insulin ... Low level of high-density lipoprotein (also known as HDL cholesterol or "good cholesterol") ...
... increasing expression of low-density lipoprotein receptors (LDL receptors) on hepatocytes. This increases LDL uptake by the ... "Drugs.com. Retrieved 3 April 2011.. *^ a b c McCrindle BW, Ose L, Marais AD (July 2003). "Efficacy and safety of atorvastatin ... Major. *Type 2 diabetes mellitus, an uncommon class effect of all statins. ... Neuvonen PJ, Niemi M, Backman JT (December 2006). "Drug interactions with lipid-lowering drugs: mechanisms and clinical ...
Nanoparticles for drug delivery to the brain
There exist many lipoprotein receptors which bind lipoproteins to form complexes that in turn transport the liposome nano- ... Toxicity is a highly important factor and limit of drug delivery studies, and a major area of interest in research on ... LDL receptor (LRP1), transferrin receptor, and insulin receptor. As long as a receptor exists on the endothelial surface of the ... Additional receptors identified for receptor-mediated endocytosis of nanoparticle delivery systems are the scavenger receptor ...
Clark L. Anderson
The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy. Adv drug Deliv Rev 91: 109-124. Chaudhury, C., S. ... The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J. Exp. Med. ... Blood-Borne Lipopolysaccharide Is Rapidly Eliminated by Liver Sinusoidal Endothelial Cells via High-Density Lipoprotein. J. ... This high affinity characteristic of IgG for FcRn is exploited by the drug industry to prolong the lifespan of protein drugs. 3 ...
... constitute a variety of drugs that block alpha-1-adrenergic receptors in arteries, smooth muscles, and central nervous system ... Alpha-1 blockers have a good effect on lipoproteins in plasma, insulin resistance and it causes the glucose levels in blood to ... Roehrborn, Claus G.; Siami, Paul; Barkin, Jack; Damião, Ronaldo; Major-Walker, Kim; Morrill, Betsy; Montorsi, Francesco (2008- ... Drugs that inhibit CYP3A4 for example itraconazol, ketoconazol and ritonavir can increase drug exposure for tamsulosin, ...
As cardiolipin is synthesized in the luminal side of inner mitochondrial membrane, a major fraction of this newly synthesized ... The extrinsic pathway is initiated by membrane bound death receptors, leading to activation of caspase 8, whereas the intrinsic ... Blood plasma of these mice showed elevated levels of non-high-density lipoproteins, cholesterol, triglycerides, non-esterified ... pathway is triggered by DNA damaging drugs and UV radiation, leading to mitochondrial depolarization and subsequent activation ...
Genome-wide complex trait analysis
Illicit Drugs: 0.37(0.102), 0.22(0.16), DSM-IV drug dependence diagnoses (DD): 0.36(0.13)factor score based on problem use (PU ... fasting high-density lipoprotein (HDL): 0.12(0.05) 0.24(0.061), 0.45(0.017) low density lipoprotein cholesterol (LDL): 0.16( ... are a major source of risk for autism", Klei et al 2012 "Most genetic risk for autism resides with common variation", Gaugler ... 2016-02-11 Divergent ah receptor ligand selectivity during hominin evolution, Troy D. Hubbard et al, 2016-08-02 Smoke signals: ...
There are 5 types of Sphingosine-1-phosphate receptor. The drug fingolimod (FTY720), which agonizes the S1P receptor, prevents ... S1P is a blood borne lipid mediator, in particular in association with lipoproteins such as high density lipoprotein (HDL). It ... In the immune system, it is now recognized as a major regulator of trafficking of T- and B-cells. S1P interaction with its ... ONO-4641 (a drug of Ono Pharmaceutical Co., Ltd.) is a sphingosine-1-phosphate (S1P) receptor agonist which keeps lymphocytes ...
The complex is endocytosed and cleared by a low-density lipoprotein-receptor-related protein. In humans, 4 different TIMPs have ... Jacobsen, J. A.; Major Jourden, J. L.; Miller, M. T.; Cohen, S. M. (2010). "To bind zinc or not to bind zinc: An examination of ... The drug is highly lipophilic and able to cross the blood brain barrier at higher doses. COL-3 accumulates in higher ... One mechanism to inhibit MMP activity is by dislodging the enzymes from their receptors. Gold salts bind to a heavy metal site ...
Drug Benefit Trends. 22: 77-88. Hotamisligil GS (June 1999). "The role of TNFalpha and TNF receptors in obesity and insulin ... Reiser S, Powell AS, Scholfield DJ, Panda P, Ellwood KC, Canary JJ (May 1989). "Blood lipids, lipoproteins, apoproteins, and ... is a major focus of contemporary pharmaceutical research. Turcotte C, Chouinard F, Lefebvre JS, Flamand N (June 2015). " ... U.S. Food and Drug Administration. "Drugs to be Discontinued". Retrieved 2013-12-11. Hatori M, Vollmers C, Zarrinpar A, ...
Furthermore, sPLA2 remodels lipoproteins, notably low-density lipoproteins (LDL) and their receptors, which are responsible for ... "Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients". Journal of ... Expert Opinions in Investigational Drugs. 19 (10): 1245-55. doi:10.1517/13543784.2010.517193. PMID 20809869. CS1 maint: ... CS1 maint: Multiple names: authors list (link) Mallat, Z., Lambeau, G., Tedgui, A. (November 2010). "Lipoprotein-Associated and ...
Lectin-like oxidized low density lipoprotein receptor-1) CD36 ENSG00000206320, ENSG00000231268, ENSG00000234729, ... The human RAGE gene lies within the major histocompatibility complex (MHC) class III region on chromosome 6 and comprises 11 ... Penumutchu SR, Chou RH, Yu C (November 2014). "Interaction between S100P and the anti-allergy drug cromolyn". Biochemical and ... Other AGE receptors are: SR-A (Macrophage scavenger receptor Type I and II) OST-48 (Oligosaccharyl transferase-4) (AGE-R1) 80 K ...
... low density lipoprotein (LDL), intermediate density lipoprotein (IDL) and high density lipoprotein (HDL). All the lipoproteins ... Consumer Reports; Drug Effectiveness Review Project (March 2013). "Evaluating statin drugs to treat High Cholesterol and Heart ... Cholesterol is one of three major classes of lipids which all animal cells use to construct their membranes and is thus ... or the LDL receptor gene. Familial hypercholesterolemia affects about one in five hundred people. Diet has an effect on blood ...
However, non-canonical Wnt5a has also been shown to bind to Ror1/2, RYK, and RTK depending on cell and receptor context to ... Differentiated tumor cells in a state of quiescence are typically not affected by drugs can may account for tumor recurrence. ... Panáková D, Sprong H, Marois E, Thiele C, Eaton S (May 2005). "Lipoprotein particles are required for Hedgehog and Wingless ... Chien, Andy J.; Moore, Erin C.; Lonsdorf, Anke S.; Kulikauskas, Rima M.; Rothberg, Bonnie Gould; Berger, Aaron J.; Major, ...
For example, peroxisome proliferator-activated receptor (PPAR) gamma agents are commonly used drugs to treat type 2 diabetes ... Proposed criteria include: Major criteria Elevated waist circumference or BMI Onset or worsening of high blood sugar with ... reduced high density lipoprotein cholesterol levels, (4) high blood pressure, and (5) high blood sugar. However, different ... Regarding drug therapies, it has been stated that: "An emerging concept is that the development of anti-obesity agents must not ...
Low density lipoprotein receptor-related protein 1 (LRP1), also known as alpha-2-macroglobulin receptor (A2MR), apolipoprotein ... Overton CD, Yancey PG, Major AS, Linton MF, Fazio S (Mar 2007). "Deletion of macrophage LDL receptor-related protein increases ... neurological disorders drug targets. 8 (1): 16-30. ISSN 1871-5273. PMC 2872930 . PMID 19275634. Storck, Steffen E.; Meister, ... domain of lipoprotein lipase binds to the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor (LRP ...
Neuromuscular junction disease
... but instead of the acetylcholine receptor, the culprits were MuSK, a muscle-specific serum kinase, and lipoprotein receptor- ... Drug-induced myasthenia gravis is also a very rare condition in which pharmacological drugs cause a blockade or disruption of ... The major signs that indicate a congenital syndrome are symptoms present at birth, such as weakness and a depressive response ... "Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor ...
Occupational health psychology
Main article: Major depressive disorder. Using data from the ECA study, Eaton, Anthony, Mandel, and Garrison (1990) found that ... These risk factors include smoking, obesity, low density lipoprotein (the "bad" cholesterol), lack of exercise, and blood ... advantages of therapy with beta-receptor blockers. Clinical and Experimental Hypertension. Part A, Theory and Practice, 7(7), ... Wang J. (2005). Work stress as a risk factor for major depressive episode(s). Psychological Medicine, 35, 865-871. doi:10.1017/ ...
කොලෙස්ටරෝල් - විකිපීඩියා, නිදහස් විශ්වකෝෂය
Low-density lipoproteins are taken into the cell by LDL receptor-mediated endocytosis in clathrin-coated pits, and then ... Grundy SM (2007). "Should women be offered cholesterol lowering drugs to prevent cardiovascular disease? Yes". BMJ 334 (7601): ... Under certain circumstances, when more concentrated, as in the gallbladder, cholesterol crystallises and is the major ... very low density lipoprotein (VLDL), intermediate density lipoprotein (IDL), low density lipoprotein (LDL) and high density ...
They later won the 1985 Nobel Prize in Medicine for their discovery of the LDL receptor and its impact on lipoprotein ... Staff (29 January 2013) FDA approves new orphan drug Kynamro to treat inherited cholesterol disorder U.S. Food and Drug ... There are five major classes of FH due to LDLR mutations: ... The LDL receptor gene is located on the short arm of chromosome ... "In vivo evidence for reduced binding of low density lipoproteins to receptors as a cause of primary moderate ...
Cyclin-dependent kinase 4
Low-density-lipoprotein receptor kinase (EC 126.96.36.199). *-. Receptor protein serine/threonine kinase (EC 188.8.131.52). *Bone ... "Approved Drugs , Ribociclib (Kisqali)". Retrieved 12 September 2017.. *^ a b c d Ewing RM, Chu P, Elisma F, Li H, Taylor P, ... Cyclin D-CDK4 complexes are major integrators of various mitogenic and antimitogenic signals. Also phosphorylates SMAD3 in a ... response to drug. • transcription initiation from RNA polymerase II promoter. • G1/S transition of mitotic cell cycle. • ...
Current Drug Targets. Inflammation and Allergy. 2 (3): 224-31. doi:10.2174/1568010033484115. PMID 14561157.. ... as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells". The Journal of Experimental Medicine ... Cathelicidin rapidly destroys the lipoprotein membranes of microbes enveloped in phagosomes after fusion with lysosomes in ... "Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response". Science. 311 (5768): 1770-3. doi:10.1126/ ...
Vitamin D toxicity
In almost every case, a low-calcium diet combined with corticosteroid drugs will allow for a full recovery within a month. It ... Keisala T, Minasyan A, Lou YR, Zou J, Kalueff AV, Pyykkö I, Tuohimaa P (July 2009). "Premature aging in vitamin D receptor ... Evidence suggests that dietary vitamin D may be carried by lipoprotein particles into cells of the artery wall and ... Cholecalciferol (shown above) and ergocalciferol are the two major forms of Vitamin D. ...
Harold E. Varmus
"A receptor for subgroup A Rous sarcoma virus is related to the low density lipoprotein receptor". Cell. 74: 1043-51. doi: ... Director, Office of National Drug Control Policy. Gil Kerlikowske. 2009-14. Angella Reid. 2011-17. Michael Botticelli. 2014-17 ... and leading a major capital campaign. He also continued to run an active laboratory and to teach as a Member of the ... building a major new laboratory facility, the Mortimer E. Zuckerman Research Center; starting a new graduate school for cancer ...
Drug candidates. Tirilazad is an antioxidant steroid derivative that inhibits the lipid peroxidation that is believed to ... Nonpolar antioxidants such as eugenol-a major component of oil of cloves-have toxicity limits that can be exceeded with the ... Here, low density lipoprotein (LDL) oxidation appears to trigger the process of atherogenesis, which results in atherosclerosis ... Many polyphenols may have non-antioxidant roles in minute concentrations that affect cell-to-cell signaling, receptor ...
Hormone replacement therapy
"Therapeutic Advances in Drug Safety. 6 (2): 45-56. doi:10.1177/2042098614568300. ISSN 2042-0986. PMC 4406918. PMID 25922653.. ... D2 receptor antagonists (prolactin releasers) (e.g., domperidone, metoclopramide, risperidone, haloperidol, chlorpromazine, ... There are five major human steroid hormones: estrogens, progestogens, androgens, mineralocorticoids, and glucocorticoids. ... With menopause, HDL decreases, while LDL, triglycerides and lipoprotein a increase, patterns that reverse with estrogen. Beyond ...
ATP-binding cassette transporter
Bacterial drug resistance has become an increasingly major health problem. One of the mechanisms for drug resistance is ... Drug RA2) Macrolide Exporter (MacB) Peptide-4 Exporter (Pep4E) 3-component Peptide-5 Exporter (Pep5E) Lipoprotein Translocase ( ... The sulfonylurea receptors (SUR), involved in insulin secretion, neuronal function, and muscle function, are also part of this ... family 3.A.1.119 Drug/siderophore exporter-3 (DrugE3) family (Putative) Drug Resistance ATPase-1 (Drug RA1) (Putative) Drug ...
In 1985, both drugs were also reported to increase serum levels of high density lipoprotein (HDL) cholesterol, total ... The gene expression of these isoenzymes is regulated by human pregnane receptor X (PXR) and constitutive androstane receptor ( ... The major metabolite, phenobarbital, is also a potent anticonvulsant in its own right and likely contributes to primidone's ... U.S. Food and Drug Administration Center for Drug Evaluation and Research. "Drug Approval Package: Keppra (Levetiracetam) ...
... a scavenger receptor for oxidized low density lipoproteins, native lipoproteins, oxidized phospholipids, and long-chain fatty ... these two diastereomers are major metabolites of 13(S)-HODE in cultured HT-29 human colon cancer cells. Colonic mucosal ... 13-HODE axis inhibits the development of drug-induced colon cancer as well as the growth of human colon cancer cell explants.[ ... TRPV1 is the transient receptor potential cation channel subfamily V member 1 receptor (also termed capsaicin receptor or ...
Health effects of tobacco
Drug interactions. Smoking is known to increase levels of liver enzymes that break down drugs and toxins. That means that ... Furthermore, the ratio of high-density lipoprotein (HDL, also known as the "good" cholesterol) to low-density lipoprotein (LDL ... Smoking is a major risk factor for heart attacks, strokes, chronic obstructive pulmonary disease (COPD) (including emphysema ... which is consistent with increased activation of dopamine receptors. Neurologically, rodent studies have found that ...
However, the use of such drugs has proven largely unsuccessful due to several challenges, including varying species receptor ... Free fatty acids are liberated from lipoproteins by lipoprotein lipase (LPL) and enter the adipocyte, where they are ... Mice have eight major adipose depots, four of which are within the abdominal cavity. The paired gonadal depots are attached ... is controlled through the balanced control of lipolytic B-adrenergic receptors and a2A-adrenergic receptor-mediated ...
Apolipoproteína E, a enciclopedia libre
Weisgraber KH, Innerarity TL, Mahley RW (Mar 1982). "Abnormal lipoprotein receptor-binding activity of the human E apoprotein ... Current Drug Targets. Cardiovascular & Haematological Disorders 1 (2): 93-106. PMID 12769659. doi:10.2174/1568006013337944.. ... "APOE genotype is a major predictor of long-term progression of disability in MS". Neurology 56 (3): 312-6. PMID 11171894. doi: ... A rexión C-terminal tamén contén un sitio de unión ao receptor de lipoproteína de baixa densidade (LDLR). ...
Hepatitis C virus
The envelope of HCV is similar to very low-density lipoproteins (VLDL) and low-density lipoproteins (LDL). Because of this ... "Food and Drug Administration. Nov 22, 2013.. *^ "Medivir: Simeprevir has been approved in Japan for the treatment of genotype 1 ... It prevents CD81 from latching onto its respective receptor on the virus. In addition, E2 can shield E1 from the immune ... A Bayesian analysis suggests that the major genotypes diverged about 300-400 years ago from the common ancestor virus. The ...
N-Acetylglucosamine receptor. *Neuropilins. *Transferrin receptor. *EDAR. *Lipoprotein receptor-related protein. *Progestin and ... Heimer, L. (2003). "A new anatomical framework for neuropsychiatric disorders and drug abuse". Am J Psychiatry. 160 (10): 1726- ... Many studies have found reduced olfactory sensitivity in patients with major depressive disorders (MDD) and dementia and ... Rats rely heavily on olfactory sensory input from olfactory receptors for behavioral attitudes. Studies show that bilateral ...
"Meveol: orphan drug status granted by the FDA for the treatment of cystic fibrosis". United States Food and Drug Administration ... It is present in the milk of humans and other mammals, in the blood plasma and neutrophils and is one of the major proteins of ... The lactoferrin receptor plays an important role in the internalization of lactoferrin; it also facilitates absorption of iron ... Many viruses tend to bind to the lipoproteins of the cell membranes and then penetrate into the cell. Lactoferrin binds to the ...
2006). Selective Estrogen Receptor Modulators a New Brand of Multitarget Drugs. Berlin, Heidelberg: Springer-Verlag Berlin ... In addition, there is an increased risk of thromboembolism especially during and immediately after major surgery or periods of ... "Effects of Tamoxifen Therapy on Lipid and Lipoprotein Levels in Postmenopausal Patients With Node-Negative Breast Cancer" ... Enrique Ravina (11 January 2011). The Evolution of Drug Discovery: From Traditional Medicines to Modern Drugs. John Wiley & ...
Major sites of cleavage by cathepsins B, D, and L". The Journal of Biological Chemistry. 266 (30): 20198-204. PMID 1939080.. ... 1lya: CRYSTAL STRUCTURES OF NATIVE AND INHIBITED FORMS OF HUMAN CATHEPSIN D: IMPLICATIONS FOR LYSOSOMAL TARGETING AND DRUG ... the agonist of formyl peptide receptor 3". Journal of Immunology. 187 (3): 1475-85. doi:10.4049/jimmunol.1003545. PMID 21709160 ... Cathepsin D enzymatic activity induces hydrolytic modification of apolipoprotein B-100-containing lipoproteins, including LDL, ...
Receptor/signaling modulators. Estrogens and antiestrogens. Androgen receptor modulators. Progesterone receptor modulators. ... Estriol is the major urinary metabolite. Estradiol is conjugated in the liver to form estrogen conjugates like ... Hochadel M (1 April 2015). Mosby's Drug Reference for Health Professions. Elsevier Health Sciences. pp. 602-. ISBN 978-0-323- ... It affects the production of multiple proteins, including lipoproteins, binding proteins, and proteins responsible for blood ...
U.S. Food and Drug Administration. Retrieved 2011-08-28.. *^ "Chicken from Farm to Table , USDA Food Safety and Inspection ... The major isoform of the human growth hormone is a protein of 191 amino acids and a molecular weight of 22,124 daltons. The ... Thus, GH exerts some of its effects by binding to receptors on target cells, where it activates the MAPK/ERK pathway. ... Maybe, Nancy G (1984). "Direct expression of human growth in Escherichia coli with the lipoprotein promoter". In Arthur P. ...
The major sphingoid base of mammals is commonly referred to as sphingosine. Ceramides (N-acyl-sphingoid bases) are a major ... Vance JE, Vance DE (2002). Biochemistry of Lipids, Lipoproteins and Membranes. Amsterdam: Elsevier. ISBN 978-0-444-51139-3. .. ... Bełtowski J (2008). "Liver X receptors (LXR) as therapeutic targets in dyslipidemia". Cardiovascular Therapeutics. 26 (4): 297- ... Current Opinion in Investigational Drugs. 9 (11): 1192-205. PMID 18951299.. ...
... and the focus of research shifted to discovering new drugs. With the introduction of sodium valproate in the 1970s, drugs were ... Several possible explanations exist for this gap between evidence and clinical practice. One major factor may be the lack ... Health issues include high levels of low-density lipoprotein, high total cholesterol, and weight loss. ... ineffective receptors for inhibitory neurotransmitters; insufficient breakdown of excitatory neurotransmitters leading to ...
"Drugs@FDA: FDA Approved Drug Products: Estradurin". United States Food and Drug Administration. Retrieved 24 June 2018.. ... Receptor/signaling modulators. Estrogens and antiestrogens. Androgen receptor modulators. Progesterone receptor modulators. ... Structural properties of major estradiol esters Estrogen. Structure. Ester(s). Relative. mol. weight. Relative. E2 contentb. ... lipoproteins, and triglycerides. These effects can result in an increased risk of thromboembolic and cardiovascular ...
کلسیم - ویکیپدیا، دانشنامهٔ آزاد
The major producers of calcium are China (about 10000 to 12000 tonnes per year), Russia (about 6000 to 8000 tonnes per year), ... cell surface receptors are activated and the secretion of parathyroid hormone occurs; it then proceeds to stimulate the entry ... often caused also by inadequate secretion of parathyroid hormone or defective PTH receptors in cells. Symptoms include ...
... receptor FepA, ferric hydroxamate uptake receptor FhuA, transporter FecA, and pyoverdine receptor FpvA ... Drug/Metabolite Transporter (small multidrug resistance transporter EmrE - the structures are retracted as erroneous) ... Major Facilitator Superfamily (Glycerol-3-phosphate transporter, Lactose permease, and Multidrug transporter EmrD) ... alpha-helical proteins in outer membranes include Stannin and certain lipoproteins, and others ...
Naturally occurring phenols
Phenols have been investigated as drugs. For instance, Crofelemer (USAN, trade name Fulyzaq) is a drug under development for ... p-Cresol and o-cresol are also components of the human sweat. P-cresol is also a major component in pig odor.[ ... via its encoding for a receptor for acetosyringone and other phenolic phytochemicals exuded by plant wounds. This compound ... assays or inhibition of copper-catalyzed in vitro human low-density lipoprotein oxidation. ...
Patent US7815943 - Cardiovascular therapy composition including transfer factor and therapeutic ... - Google Patents
The composition may also include one or more of the following: an LDL receptor-binding element; a blood flow-enhancing element ... Lipoprotein(a) ("Lp(a)") binds LDL receptors on the walls of blood vessels. Lp(a) also binds lysine-sepharose, immobilized ... Thus, the efficacy of LDL-reducing drugs and therapies continues to be a source of major debate within the medical community. ... Since LDL receptor-binding elements are capable of occupying the sites on LDL receptors to which Lp(a) and LDL bind, LDL ...
Diabetes and Metabolism Journal
... are potent lipid-modifying drugs. Their main effects are reduction of triglycerides and increase in high-density lipoprotein ... Recent discovery of its receptor, glial cell line-derived neurotrophic factor (GDNF) family receptor α-like (GFRAL), suggests a ... Glucotoxicity, lipotoxicity, and glucolipotoxicity have been suggested to be a major cause of β-cell dysfunction for deca.... ... Enhancer-Gene Interaction Analyses Identified the Epidermal Growth Factor Receptor as a Susceptibility Gene for Type 2 Diabetes ...
Anti-PCSK9 Drugs: An Ingenious Solution For A Problem That's Mostly Already Solved
Antibodies against PCSK9 point to the future of drug discovery. Unfortunately, in the decade it has taken to bring them to ... Since PCSK9 is a protease that breaks down the LDL receptor, itself the major clearance mechanism for cholesterol from the ... and in particular the triglyceride-rich lipoproteins, such as LDL, that are implicated in causing cardiovascular disease. ... Since PCSK9 is a protease that breaks down the LDL receptor, itself the major clearance mechanism for cholesterol from the ...
Associations of ApoAI and ApoB-Containing Lipoproteins With AngII-Induced Abdominal Aortic Aneurysms in MiceSignificance |...
HDL is the major lipoprotein fraction in plasma of male C57BL/6 mice (Figure 1B), and apoAI is the predominant structural ... Low-density lipoprotein receptor−/− mice fed normal diet had low incidence of AngII-induced AAAs. Western diet feeding of this ... mice administered ezetimibe and fed normal laboratory diet were not attributed to a direct effect of the drug. These findings ... Chronic angiotensin II infusion promotes atherogenesis in low density lipoprotein receptor -/- mice. Ann N Y Acad Sci. 1999;892 ...
AEGR Pulls Back, But Remains Sheltered From Major Losses | Featured Content
... drug Juxtapid (lomitapide), Aegerion Pharmaceuticals (NASDAQ: AEGR) finally ... another protein that is involved in the formation of lipoproteins and acts as a ligand for LDL receptors. ... 50/share or so based on the pricing of the drug and the efficacy profile that the drug has established up to this point. This ... The prices of the two drug (patient/year) are extremely high too - at $295,000 and $176,000. This pricing makes it feasible for ...
2004) Membrane transporter/receptor-targeted prodrug design: strategies for human and veterinary drug development. Adv Drug ... United States Food and Drug Administration. LDL. low-density lipoprotein. MB07133. 4-amino-1-(5-O-(2-oxo-4-(4-pyridyl)-1,3,2- ... The major metabolic pathway for losartan is through CYP2C9 with some contribution from CYP3A4 (Sica et al., 2005). In patients ... A drug interaction occurs when the effects of a drug are markedly altered as a result of coadministration of another drug. Drug ...
Where to buy dostinex in uk
Treatment to mediate metabolic effects of the malarial drugs for nine months. The major elective cardioversion is a relatively ... Most enteric bacteria, as to patients with zinc oxide, but only be complicated by v2-receptors. EGFR receptor modulators and ... Epidemiological observations, hepatitis is sensitive, intermediate-density lipoprotein, lethargy In the brain at all members of ... These drug therapy, a maximum activity, a lower-affinity/higher- capacity of where to buy dostinex in uk common of the heart ...
Potential of PCSK9 as a new target for the management of LDL cholester | RRCC
The additional low-density lipoprotein cholesterol lowering obtained with PCSK9 inhibition will be able to reduce the ... The discovery of proteins regulating the activity of the low-density lipoprotein receptor has been a major breakthrough in the ... development of new cholesterol-lowering drugs. This review describes inhibition of proprotein convertase subtilisin/kexin type ... of the low-density lipoprotein receptor has been a major breakthrough in the development of new cholesterol-lowering drugs. ...
Pravastatin - Wikipedia
Pravastatin acts as a lipoprotein-lowering drug through two pathways. In the major pathway, pravastatin inhibits the function ... which are the precursor to low-density lipoproteins (LDL). These reductions increase the number of cellular LDL receptors, thus ... In 2005, Pravachol was the 22nd-highest selling brand-name drug in the United States, with sales totaling $1.3 billion. The U.S ... Pravastatin (marketed as Pravachol or Selektine) is a member of the drug class of statins, used in combination with diet, ...
SOST and DKK: Antagonists of LRP Family Signaling as Targets for Treating Bone Disease
These mutations were either in the gene encoding the low density lipoprotein receptor-related protein-5 (LRP5) or in a gene ( ... This work has established LRP5 as a major target for drug development to treat osteoporosis and other bone diseases. This paper ... Y.-F. Guo, D.-H. Xiong, H. Shen et al., "Polymorphisms of the low-density lipoprotein receptor-related protein 5 (LRP5) gene ... T. Fujino, H. Asaba, M.-J. Kang et al., "Low-density lipoprotein receptor-related protein 5 (LRP5) is essential for normal ...
Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARγ agonist | PNAS
retinoid X receptor;. LDL,. low-density lipoprotein;. azPC,. hexadecyl azelaic phosphatidylcholine;. SV40,. simian virus 40. ... Transfection studies in yeast, which lack nuclear hormone and LPAx receptors, show that LPA directly activates PPARγ. A major ... We show that LPA, but not its precursor phosphatidic acid, displaces the drug rosiglitazone from the ligand-binding pocket of ... LPAx Receptor Activation.. LPA receptor activation was evaluated by examining Ca2+ flux in fura-2-loaded Sf9 cells expressing ...
Recent Dissertations - Bioinformatics Program
... drug design techniques to identify anti-atherosclerotic drugs using the lectin-like oxidized low-density lipoprotein receptor 1 ... Atherosclerotic related diseases are a major cause of death in the United States. LOX-1 mediates the internalization of ox-LDL ... Drug Discovery and Development Conference. *Drug Discovery and Development Colloquium 2018. *DDDC Site Venue and Hotel ... Computer-aided rational drug design is one of the most promising approaches for the development of effective drug therapies. ...
Patent US5939331 - Red blood cell separation means for specific binding assays - Google Patents
... receptor/receptor ligands; enzyme/substrate; enzyme/inhibitor and lectin/carbohydrate.. Suitable analytes include soluble ... analytes such as hormones, enzymes, lipoproteins, bacterial or viral antigens, immunoglobulins, lymphokines, cytokines, drugs, ... Yet another major group comprises oligonucleotide sequences which react specifically with other oligonucleotides or protein ... A wide range of antigenic polysaccharides, lipopolysaccharides, lipoproteins, proteoglycans and glycoproteins can also be ...
Acid sphingomyelinase - Wikipedia
... ligation of death receptors, and chemotherapy drugs. The main mechanism of trafficking L-SMase to the lysosome is through the ... The lysosomal acidic SMase is considered one of the major candidates for the production of ceramide in the cellular response to ... S-SMases are zinc-dependent, and have been implicated in the metabolism of lipoprotein-bound SM to Ceramide and the aggregation ... Acid SMase has been shown to accelerate atherosclerotic lesion progression through promoting aggreation of lipoproteins to ...
Natural Alternatives to Heart Medication | Health and Nutrition Advice on Patrick Holford.com
The major side effect of these drugs is excessive bleeding, such as eye and brain hemorrhages, blood in the urine, and bleeding ... lipoprotein (a) level, which is a highly significant risk factor; and C-reactive protein level, which indicates inflammation in ... angiotensin II receptor antagonists, calcium channel blockers, and nitrovasodilators, all of which are designed to lower blood ... The major trials of statin drugs excluded those with class 3 and 4 heart failure, thus avoiding the chances of seeing an ...
Most common side effects bactrim ds
The major adverse effects of lipoprotein fraction of dextropropoxyphene inhibit na/K/2Cl Most of undetermined cause mental ... 2%, while awaiting heart-lung transplant- ation of parent drug, and congestive cardiac arrest. The important to the portion is ... Treatment with an h2-blocker leukotriene receptor causing arterial disease. Women leukotriene antagonists suppress their pupils ... The major adverse effects of lipoprotein fraction of dextropropoxyphene inhibit na/K/2Cl. After having resolved does pepcid ...
PPARalpha and dyslipidemia
An important group of drugs used in the treatment of dyslipidemia are the fibrates. Fibrates serve as agonists for the ... Dyslipidemia is defined by abnormal levels of plasma lipoproteins. Several different types of dyslipidemia can be distinguished ... Apart from its major actions outlined above, PPARalpha modulates lipoprotein metabolism in several other ways, mostly via ... Fibrates serve as agonists for the peroxisome proliferator-activated receptor alpha (PPARalpha), a ligand-activated ...
JLR] A Disruption Is Statin'
Increased PCSK9 activity increases cholesterol levels by binding to low-density lipoprotein receptors (LDLR), which induces ... Proprotein convertase subtilisin kexin type 9 (PCSK9) is a major player in cholesterol regulation - mutations in this gene can ... a widely prescribed cholesterol-reducing drug, increases serum PCSK9 levels while lowering total cholesterol, triglycerides and ... receptor degradation and the accumulation of low-density lipoproteins (LDL) in the bloodstream. Thus, high PCSK9 levels ...
SVEC4-10EE2 ATCC ® CRL-2167™ Mus musculus
They form tube-like structures in the presence of suramin, a drug which blocks growth factor receptors. ... high affinity receptors for low density lipoprotein and vascular cell adhesion molecule (VCAM). ... The cells express the cell surface major histocompatibility complex class I antigen, H-2 k of the parental cell line, and ...
Study on synthesis and properties of nanoparticles loaded with amaryllidaceous alkaloids, Open Life Sciences | 10.1515/biol...
... brain targeting of amaryllidaceous alkaloids was enhanced by considering low density lipoprotein (LDL) receptors of blood-brain ... In addition, drug loading rate, encapsulation rate, and drug release by the nanoparticles were determined to assess the quality ... AbstractAlzheimers disease (AD) is the most common disease among the elderly people and a major social and medical problem. ... In addition, drug loading rate, encapsulation rate, and drug release by the nanoparticles were determined to assess the quality ...
Patent US6687395 - System for microvolume laser scanning cytometry - Google Patents
... antigen receptors (such as the B cell receptor and the T cell receptor), and major histocompatibility complex. Each of these ... In one important embodiment, the MLSC system is used to measure changes in the concentration of drugs and drug metabolites in ... Soluble factors include, but are not limited to, soluble proteins, carbohydrates, lipids, lipoproteins, steroids, other small ... drugs and drug metabolites.. As used herein the term "small molecule" or "organic molecule" or "small organic molecule" means a ...
Little Pharmacy: 500 mg lasix no prescription RX mall
... low-density lipoprotein ldl receptor family members smoke. It forms in the year . Nephrotic syndrome: Nephrotic syndrome is a ... Patient-generated passive circuitry: Haemofiltration can be delayed if drugs with durations of action and side effects are ... formamide is stored in a hetinstalla s pathology of human arpkd gene on chromosome pkhd which encodesbrocystin ward the major ... have been doctor shopping or at receptor mrna in whole embryos for a. Following a chronic illness. This individual evaluation ...
nk cell lymphoblastic lymphoma drug therapy 2000:2010[pubdate] *count=100 - BioMedLib™ search engine
Receptors, Lipoprotein; 0 / Ribosome Inactivating Proteins, Type 1; 0 / high density lipoprotein receptors; 147605-06-9 / high ... MeSH-major] Antibody Formation / drug effects. Antineoplastic Agents / adverse effects. Immunity, Cellular / drug effects. ... Major-Mesh. And for this query matching the MeSH-Major terms: + Mesh. And for this query matching any MeSH terms: + Journal. ... MeSH-major] Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / radiotherapy. *[MeSH-minor] Adolescent. Adult. Aged. Child. ...
brown fat tumour drug 2000:2010[pubdate] *count=100 - BioMedLib™ search engine
Lipoprotein Lipase / genetics. Lipoprotein Lipase / metabolism. Mice. Mifepristone / pharmacology. Mineralocorticoid Receptor ... Major-Mesh. And for this query matching the MeSH-Major terms: + Mesh. And for this query matching any MeSH terms: + Journal. ... MeSH-major] Adipose Tissue / metabolism. Seminal Plasma Proteins / physiology. *[MeSH-minor] Adipocytes / drug effects. ... MeSH-major] Adipose Tissue, Brown / drug effects. Adipose Tissue, Brown / metabolism. Carrier Proteins / genetics. ...
A quantitative approach to study indirect effects among disease proteins in the human protein interaction network | BMC Systems...
The most influenced diabetes protein was P51681 (CCR5_HUMAN), C-C chemokine receptor type 5, a receptor for a number of ... We suggest that the central proteins in the IP network can be even more important in systems-based medicine and drug design ... 26] suggested that genetic variation in the ADRB2 gene might be of major importance for obesity, energy expenditure, and ... P07550 belongs to the group of disulfide bond, glycoprotein, lipoprotein, palmitate and phosphoprotein. The findings of Large ...
Can you use celexa for bipolar
Two major efferent of nausea, including penicillin-resistant strains of these drugs or loss. D4T previously have caused by ... Low-density lipoprotein fraction have also toxic and in males and breast-feeding. The negative charges that steroid oral agents ... Fluid must be playing his blood flow 33% of allergic asthma by face receptors, e. Tolbutamide and preferably for intravenous ... Recent studies, reteplase and the drug of gnRH. There is often causes heavy alcohol in the host kinases. Digoxin has to undergo ...
PCSK9 from ACROBiosystems : Get Quote, RFQ, Price or Buy
PCSK9 binds to the epidermal growth factor-like repeat A (EGF-A) domain of the low-density lipoprotein receptor (LDLR), ... Number of Launched Drugs４2. Number of Drugs in Clinical Trials４22. Lastest Research Phase４Approved ... This protein plays a major regulatory role in cholesterol homeostasis.. ...
Gemfibrozil | Glucuronide Conjugation | QSAR | 2D Descriptors | Mechanism-based Inhibition | CYP2C8
Mechanism-based inhibition of cytochrome P450 involves the bioactivation of the drug to a reactive metabolite, which leads to ... activated receptor alpha (PPARα) stimulation. It has been reported that the concomitant use of gemfibrozil with other drugs, ... The role of the major descriptors in the QSAR model can be visualised in the correlation matrix, shown in Table 4. It indicates ... Gemfibrozil reduces the triglyceride levels and increases high-density lipoprotein (HDL) levels in the patients . Its ...
Lipoprotein (a) Blood SST (Test Code 4009) - NutriPATH Integrative and Functional Pathology Services.
Uptake via the LDL receptor is not a major pathway of Lp(a) metabolism. The kidney has been identified as playing a role in Lp( ... Most commonly prescribed lipid-reducing drugs have little or no effect on Lp(a) concentration. ... Lipoprotein (a) is an independent risk factor for vascular disease. Lipoprotein (a) has many properties in common with low ... Lipoprotein (a) Blood SST (Test Code 4009). Collection Method. SST Serum Blood Test ...
Cholesterol drugs <b>(Fibrate Warning: Tricor (fenofibrate) and Lopid (gemfibrozil))</b>(Steven B....
These drugs induce a marked reduction of total and low-density lipoprotein (LDL) cholesterol and an increase of high-density ... Two major trials have been done since then: VA-HIT in 6,144 patients which found a reduction in cardiac events but not cardiac ... Central to their mode of action is activation of certain nuclear receptors in cells. There is no necessary connection, however ... Diet and drugs are the main instruments available to normalize lipid levels. The choice of drug to combine with diet must be ...
LDLRLipaseApoB-containing lAbnormal levels of plasma lipoproteinsDensity lipoprotein receptorsVLDLPlasma lipoproteinsPCSK9StatinCardiovascularParticlesPathwayBindsCholesterol levelsProteinLigandIntermediate-density lipStimulate lipoproteinAgonistLeukotriene receptor aPeptideAtherogenicSerumSignificantlyLiver X receptPatientsIntracellularSynthesisFarnesoid X ReceptProteinsKexin typeAtheroscleroticExpressionCoronaryInhibitHypercholesterolemiaTumorGeneHighAffinityTargetsDecrease
- Increased PCSK9 activity increases cholesterol levels by binding to low-density lipoprotein receptors (LDLR), which induces receptor degradation and the accumulation of low-density lipoproteins (LDL) in the bloodstream. (asbmb.org)
- PCSK9 binds to the epidermal growth factor-like repeat A (EGF-A) domain of the low-density lipoprotein receptor (LDLR), inducing LDLR degradation. (news-medical.net)
- SREBP2 activation increases the expression of low-density lipoprotein receptor (LDLR) on the cell surface, thus facilitating an increased uptake of cholesterol-rich low-density lipoprotein (LDL) particles from the systemic circulation. (aspetjournals.org)
- Linkage and family-based studies identified genes with now well-established roles in disease pathogenesis, such as the LDL receptor (LDLR) ( 3 ), apolipoprotein B (apoB) ( 4 ), and proprotein convertase subtilisin/kexin type 9 (PCSK9) ( 5 ). (frontiersin.org)
- Missense mutations in PCSK9 cause an autosomal dominant form of hypercholesterolemia in humans, likely due to a gain-of-function mechanism because overexpression of either WT or mutant PCSK9 reduces hepatic LDL receptor protein (LDLR) in mice. (pnas.org)
- Increased LDLR protein led to increased clearance of circulating lipoproteins and decreased plasma cholesterol levels (46 mg/dl in Pcsk9 -/- mice versus 96 mg/dl in WT mice). (pnas.org)
- Statins, a class of drugs that inhibit cholesterol synthesis, increase expression of sterol regulatory element-binding protein-2 (SREBP-2), a transcription factor that activates both the Ldlr and Pcsk9 genes. (pnas.org)
- The activity of the low-density lipoprotein receptor (LDLR) in liver is the major determinant of plasma LDL cholesterol concentrations ( 1 , 2 ). (pnas.org)
- Approximately 50% of VLDL remnants are removed by the liver via the LDLR, and the remainder mature into LDL, the major cholesterol transport particle in the blood. (jci.org)
- Activation of PPARalpha results in a reduction of plasma TG levels, which is achieved by: (1) induction of genes that decrease the availability of TG for hepatic VLDL secretion, and (2) induction of genes that promote lipoprotein lipase-mediated lipolysis of TG-rich plasma lipoproteins. (nih.gov)
- Low-density lipoprotein lipase, didanosine, but the respiratory infections, bone marrow suppression causing blurred vision. (imagenenaccion.org)
- Fibrates activate peroxisome proliferator activated receptor (PPAR) alpha, increasing the activity of lipoprotein lipase, which causes a decrease in triglyceride levels. (medscape.com)
- Common complications of bacterial fatty acids that genetically determined by lipoprotein lipase and lDL. (st-systemtronic.com)
- The effects are more than tablets can occur and major meals or by lipoprotein lipase, if bacterial agents. (interracialmarriageandfamily.com)
- To determine the effects of LY518674 on the activity of lecithin cholesterol acyltransferase (LCAT), cholesterol ester transfer protein (CETP), lipoprotein lipase, hepatic lipase, and endothelial lipase. (clinicaltrials.gov)
- Dietary cholesterol and triglycerides are packaged with apolipoproteins in the enterocytes of the small intestine, secreted into the lymphatic system as chylomicrons (CM). As chylomicrons circulate, the core triglycerides are hydrolyzed by lipoprotein lipase, resulting in the formation of chylomicron remnants (CM Rem), which are rapidly removed by the liver. (jci.org)
- This is due to its ability to increase the activity of lipoprotein lipase and decrease the activity of hormone-sensitive lipase, thus creating a net flux of fat into fat cells. (blogspot.com)
- They have hormone-sensitive lipase and lipoprotein lipase on their fat cells, and they are regulated by insulin in the same manner as they are in humans. (blogspot.com)
- To determine whether reductions in apoB-containing lipoproteins influenced AngII-induced AAAs, ezetimibe was administered at a dose that partially reduced plasma cholesterol concentrations to ApoE-deficient mice fed Western diet. (ahajournals.org)
- Conclusions- ApoB-containing lipoproteins contribute to augmentation of AngII-induced AAA in male mice. (ahajournals.org)
- The reduction in intracellular cholesterol concentration induces a low-density lipoprotein receptor (LDL-R) expression on the hepatocyte cell surface, which results in increased extraction of lowdensity lipoprotein cholesterol (LDL-C) from blood and decrease in concentration of circulating LDL-C and other apoB-containing lipoproteins including TG-rich particles. (omicsonline.org)
Abnormal levels of plasma lipoproteins1
Density lipoprotein receptors1
- To determine the effects of LY518674 on high-density lipoprotein (HDL), low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL) particle size using nuclear magnetic resonance (NMR). (clinicaltrials.gov)
- The key predisposing factor is the development of hypertriglyceridaemia, in particular elevation in the plasma concentration of large, triacylglycerol-rich VLDL (very-low-density lipoprotein). (biochemsoctrans.org)
- Statins remove VLDL particles via receptor-mediated pathways and reduce the residence time (and hence limit the potential for remodelling) of LDL in the circulation. (biochemsoctrans.org)
- VLDL, very-low-density lipoprotein. (biochemsoctrans.org)
- Since PCSK9 is a protease that breaks down the LDL receptor, itself the major clearance mechanism for cholesterol from the blood, blocking PCSK9 increases the level of LDL receptor and therefore dramatically reduces circulating cholesterol, and in particular the triglyceride-rich lipoproteins, such as LDL, that are implicated in causing cardiovascular disease. (forbes.com)
- Anti-PCSK9 antibodies are the jewel in the crown of modern genomic medicine, illustrating what many hope will be a paradigm for future drug discovery. (forbes.com)
- The additional low-density lipoprotein cholesterol lowering obtained with PCSK9 inhibition will be able to reduce the additional risk, but its effect on cardiovascular events has to be evaluated in future studies. (dovepress.com)
- Proprotein convertase subtilisin kexin type 9 (PCSK9) is a major player in cholesterol regulation - mutations in this gene can lead to familial hypercholesterolemia, a genetic disorder characterized by abnormally high cholesterol levels and cardiovascular disease. (asbmb.org)
- While a number of these loci harbor gene targets of currently approved therapies, such as statins and PCSK9 inhibitors, the majority of the annotated genes at these loci encode for proteins involved in vessel wall function with no known drugs available. (frontiersin.org)
- Recently it was revealed that the secreted Proprotein Convertase Subtilisin Kexin 9 (PCSK9) binds with LDL-receptor (LDL-R) causing its degradation in the lysosome with the result of LDL-C accumulating in the blood. (sigmaaldrich.com)
- Repatha is an investigational fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that reduces the liver's ability to remove low-density lipoprotein cholesterol (LDL-C), or "bad" cholesterol, from the blood. (amgen.com)
- His lab showed that PCSK9 was capable of destroying the LDL receptor, which clears LDL from the bloodstream. (rockefeller.edu)
- Paris and Tarrytown, NY - September 12, 2018 - Sanofi and Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for Praluent ® (alirocumab) Injection, a PCSK9 inhibitor. (yahoo.com)
- Praluent inhibits the binding of PCSK9 (proprotein convertase subtilisin/kexin type 9) to the LDL receptor and thereby increases the number of available LDL receptors on the surface of liver cells to clear LDL, which lowers LDL-C levels in the blood. (yahoo.com)
- Statin Drugs - Overall, statin medication can be expected to lower LDL cholesterol concentration by an average of 68 mg/dL if taken for several years. (patrickholford.com)
- Because statin drugs block production of CoQ10, they also lead to CoQ10 deficiency, a fact that has been well established in human trials. (patrickholford.com)
- The major trials of statin drugs excluded those with class 3 and 4 heart failure, thus avoiding the chances of seeing an increase in death from congestive heart failure from statin medication. (patrickholford.com)
- Statin drugs inhibit 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR), the rate-limiting enzyme in the pathway of cholesterol biosynthesis. (aspetjournals.org)
- As with all statin like drugs the major side effect is myalgia or myalgia like symptoms. (medisave.ca)
- Currently the statin drugs which inhibit the enzyme HMG-CoA reductase responsible for cholesterol synthesis in the liver are very effective in lowering LDL-cholesterol. (sigmaaldrich.com)
- Drug sales advanced by 8.3% to $235.4 billion, propelled by doubledigit growth in anticholesterol and antihypertension drugs, and by new drug entries such as Eli Lilly's depression drug Cymbalta and Vytorin, a statin and cholesterolreducer combination drug from Merck/Schering- Plough. (pharmacytimes.com)
- Post-mortem analysis of AD brains reveal a loss in cholesterol content and this make the therapeutical use of statin-like drugs quite a lot controversial. (eurekaselect.com)
- Biondi Elisa, " Statin-Like Drugs for the Treatment of Brain Cholesterol Loss in Alzheimers Disease", Current Drug Safety (2007) 2: 173. (eurekaselect.com)
- In addition, the FDA recently approved an update to the Praluent Prescribing Information to include clinical information regarding its use in patients with heterozygous familial hypercholesterolemia (HeFH) who require additional lowering of LDL-C (low-density lipoprotein cholesterol) along with diet and maximally-tolerated statin therapy and who are undergoing apheresis treatment. (yahoo.com)
- Increased plasma lipoprotein levels have been significantly correlated with cardiovascular disease. (nutripath.com.au)
- Cardiovascular disease constitutes a major health issue worldwide. (universiteitleiden.nl)
- The Canakinumab Antiinflammatory Thrombosis Outcome Study (CANTOS) has shown that interleukin (IL)-1β blockade reduces the incidence of cardiovascular events in patients with previous myocardial infarction and C-reactive protein levels >2 mg/L. These data confirm the connection between lipids and inflammation, as lipids activate the Nod-like receptor protein 3 inflammasome that leads to IL-1β activation. (ovid.com)
- LDL-lowering drugs are the foundation of cardiovascular prevention. (ovid.com)
- However, both therapies are not at the same level, given the large evidence showing that LDL-lowering drugs reduce cardiovascular risk as opposed to only one randomized trial of IL-1β blockade. (ovid.com)
- 1 FH reduces the catabolism of low-density lipoprotein cholesterol (LDL-c) and increases rates of premature atherosclerotic cardiovascular disease (CVD). (mja.com.au)
- In the lovastatin group there was a significant reduction in the number of patients with major cardiovascular events relative to the placebo group (5 vs 14) and a significant reduction in all-cause mortality (1 vs 8) however, it was not powered to demonstrate a reduction in the risk of coronary morbidity and mortality. (medisave.ca)
- Recent studies continue to show that glucose-lowering agents such as the GLP-1 receptor agonists liraglutide and semaglutide and SGLT-2 inhibitors empagliflozin and canagliflozin reduce the risk of major cardiovascular events. (medpagetoday.com)
- Well, it turns out that thanks to the Food and Drug Administration's Guidance in 2008 on novel diabetes drugs needing to show cardiovascular safety, we've subsequently stumbled on the fact that a couple of novel classes of diabetes drugs have a benefit, not just for safety, but actually a benefit in terms of reducing cardiovascular events. (medpagetoday.com)
- Regardless of their mechanism of action, these drugs in the cardiovascular outcomes trials examining their safety, we've actually found that each independently reduce cardiovascular risk. (medpagetoday.com)
- And one of the drugs, liraglutide, has a cardiovascular indication to reduce risk. (medpagetoday.com)
- But amazingly enough, in multiple clinical trials now we see a profound reduction in cardiovascular risk in patients with diabetes treated with these drugs. (medpagetoday.com)
- Out of the Diabesity consortium, including 27 partners from 10 European countries studying the physiology of adipose systems regulation among many other things, an important contribution also came out to the work of an international team of scientists who identified a gene locus that could lead to the development of new drugs to fight cardiovascular disease. (europa.eu)
- Elevated lipoprotein concentrations are a major risk factor for the development of atherosclerotic cardiovascular disease. (clinicaltrials.gov)
- High level of Low Density Lipoprotein-Cholesterol (LDL-C) in circulation in the blood is associated with an elevated risk of cardiovascular disease (CVD) and stroke. (sigmaaldrich.com)
- Low-density lipoprotein cholesterol levels in adults with type 2 diabetes: An alternative equation for accurate estimation and improved cardiovascular risk classification. (freethesaurus.com)
- The sBLA outlines a proposed update to the Prescribing Information to include the effect of Praluent in reducing the overall risk of major adverse cardiovascular events (MACE). (yahoo.com)
- A collaboration of researchers from the Lawrence Berkeley National Laboratory and the Children's Hospital of Oakland Research Institute (CHORI) have demonstrated, through in vitro studies, the potential for nanosized synthetic particles of low density lipoprotein, or LDL, to be used as a safe and effective means of delivering anticancer drugs to glioblastoma multiforme tumors. (lbl.gov)
- Trudy Forte (right) and Mina Nikanjam led the study showing that nanosize particles of synthetic low density lipoprotein selectively bind to tumor cells of glioblastoma multiforme, a deadly form of brain cancer. (lbl.gov)
- The question whether hypertriglyceridemia causes coronary artery disease (CAD) or is simply a marker for the accompanying lipoprotein abnormalities (especially low HDL cholesterol levels and small dense LDL particles) is still controversial. (diabetesjournals.org)
- A direct atherogenic effect of TG-rich particles, particularly intermediate-density lipoprotein, and remnant particles has been presumed. (diabetesjournals.org)
- The lipoprotein class comprises a number of distinct subfractions, and is commonly divided into large, intermediate and small sized particles. (biochemsoctrans.org)
- Breslow's studies have focused on molecules called apolipoproteins, which coat lipoprotein particles and determine their synthesis, processing, and breakdown. (rockefeller.edu)
- In the major pathway, pravastatin inhibits the function of hydroxymethylglutaryl-CoA (HMG-CoA) reductase. (wikipedia.org)
- The main mechanism of trafficking L-SMase to the lysosome is through the mannose 6-phosphate receptor mediated pathway. (wikipedia.org)
- The HMN formulation effectively codelivered NLS-Dox and anti-miR21 into Dox-resistant breast cancer MCF7/ADR cells and wild-type MCF7 cells via a high-density-lipoprotein receptor-mediated pathway, which facilitated the escape of Pgp drug efflux. (dovepress.com)
- These mutations were either in the gene encoding the low density lipoprotein receptor-related protein-5 ( LRP5 ) or in a gene ( SOST ) encoding a protein (Sclerostin) that potentially binds and regulates the function of LRP5 and its family members LRP4 and LRP6. (hindawi.com)
- Part one hour of therapy, this virus receptor complex then binds to patienthencounter. (roanokechowan.edu)
- [ 54 ] Niacin also reliably and significantly lowers LDL cholesterol levels, which the other major triglyceride-lowering medications do not. (medscape.com)
- Pravastatin produces consistent dose-dependent reductions in both total and low density lipoprotein (LDL)-cholesterol levels in patients with primary hyper-cholesterolaemia. (springer.com)
- Favourable changes in other parameters such as total triglyceride and high density lipoprotein (HDL)-cholesterol levels are generally modest. (springer.com)
- Lomitapide is a selective inhibitor of microsomal transfer protein (MTP), which is involved in the assembly of lipoproteins that ultimately build LDL levels in HoFH patients. (biomedreports.com)
- One such example was the body of work that resulted in the identification of the Low Density Lipoprotein-Related Protein (LRP5) as a key regulator of bone mass. (hindawi.com)
- LPA stimulates three G protein-linked, plasma membrane-associated receptors [LPA 1 , LPA 2 , and LPA 3 , formerly edg2, edg4, and edg7 ( 6 )] that recognize extracellular LPA ( 7 ). (pnas.org)
- Understanding HLA-peptide binding is essential for the development of vaccines and protein therapies, the identification of methods to prevent autoimmune diseases and the prediction of adverse drug reactions. (ualr.edu)
- Since the HLAs and peptides are two core components to trigger immunologic responses, the complete Class I HLA-binding peptidome accomplished in this study provides the scientific community a rich source for understanding the interactions between Class I HLAs and peptides, potentially assisting in the development of vaccines and protein therapeutics, facilitating studies of autoimmune diseases and improving the prediction of drug adverse reactions. (ualr.edu)
- This protein plays a major regulatory role in cholesterol homeostasis. (news-medical.net)
- Previous studies showed that knockdown of ITSN-1s (KD ITSN ), an endocytic protein involved in regulating lung vascular permeability and endothelial cells (ECs) survival, induced apoptotic cell death, a major obstacle in developing a cell culture system with prolonged ITSN-1s inhibition 1 . (jove.com)
- This protein is also a component of other multisubunit complexes e.g. thyroid hormone receptor-(TR-) associated proteins which interact with TR and facilitate TR function on DNA templates in conjunction with initiation factors and cofactors. (nih.gov)
- One of the major pathological hallmarks of the disease are amyloid plaques, composed primarly of insoluble fibrils of Aβ peptide: this molecule derives from the processing of the transmembrane amyloid precursor protein (APP) by different secretases and its production is a physiological event, but the anormal increase in Aβ levels appears to be toxic both in vitro and in vivo. (eurekaselect.com)
- 2015. Protein Kinase C is involved in the induction of ATP-Binding cassette transporter A1 expression by liver X receptor/retinoid X receptor agonist in human macrophages . (cardiff.ac.uk)
- this corresponds to harrison stage fales in x laevis and at receptor mrna localized to the external growth factors and signaling protein rgs dei nes a major determinant of morphogenesis is intimately intertwined with the exponential growth in the genitourinary tract and the nephric mesoderm cells are likely to injure the minor calyces and collecting. (nationalnewstoday.com)
- Individuals with natural mutations in PCSK-9 have less heart disease, and this is what prompted development of drugs to target this particular protein. (yu.edu)
- Certain ligand-activated nuclear receptors provide promising new targets for this purpose. (ahajournals.org)
- Nuclear receptors are transcription factors that, on ligand binding by specific molecules and cofactor recruitment, regulate the expression of specific target genes. (ahajournals.org)
- The peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors that belong to the superfamily of nuclear hormone receptors and play an important role in nutrient homeostasis [ 1 - 3 ]. (hindawi.com)
- Modified Citrus Pectin (MCP) acts as a ligand for galectin-3, which plays a major role in tumor formation and progression (7) (8) . (mskcc.org)
Leukotriene receptor a2
- LPA also is generated during platelet activation ( 5 ) to become a major growth factor of serum. (pnas.org)
- The high concentration of selenium in the Brazil nut may improve serum lipoprotein, due to its stimulation of the metabolically active form of thyroid hormones. (biomedcentral.com)
- The present study investigated the effects of a healthy diet associated with defatted Brazil nut flour on thyroid hormones and in serum lipoproteins in dyslipidemic and hypertensive patients. (biomedcentral.com)
- We showed the Class I HLA-binding peptidome could significantly improve prediction of adverse drug reactions through binding to Class I HLA using molecular docking. (ualr.edu)
- FDA and EMA guidance documents indicate that for clinical approval of new drugs for the treatment of NASH, trials should include patients who have significantly higher risk of progression to cirrhosis and hepatic decompensation, as defined as those who have biopsy-proven NASH with stage 2 fibrosis or higher. (bmj.com)
- Nuclear companies outside Mexico City, while significantly receptors same as anabolic steroids. (3riversstadium.com)
Liver X recept1
- Although many have pointed out the tiny pool of patients that Aegerion and competitor ISIS will be fighting over, Aegerion has the luxury of commercializing the most efficacious drug in the indication (based on clinical trial data). (biomedreports.com)
- Most enteric bacteria, as to patients with zinc oxide, but only be complicated by v2-receptors. (diarimaresme.com)
- EGFR receptor modulators and green, thereby coun- ters these patients at work load of hypertension. (diarimaresme.com)
- Conceptually, several major problems may exist in the anti-endotoxin strategies employed to date, none of which have used a diagnostic assay to identify patients who might benefit from anti-LPS target-directed therapy. (biomedcentral.com)
- In impotent patients suggests that are negative inotropic drugs that hepatic conjugation figure, and breast-feeding. (imagenenaccion.org)
- STEMI patients benefit, including pulsed doses of about the colon motility through- out the same drug resistance. (imagenenaccion.org)
- We used publicly available data reporting major adverse CV events (MACE) rates from other cohorts of HoFH patients to compare event rates for an equivalent number of patient years of exposure (98) in the lomitapide extension trial (NCT00943306). (biomedcentral.com)
- There were fewer major CV events per 1000 patient months of treatment in patients taking lomitapide, mipomersen or evolocumab than reported in the mipomersen cohort prior to starting mipomersen. (biomedcentral.com)
- Patients with haematological effects are susceptible, which is the drug treat- ing. (st-systemtronic.com)
- Doxazosin improves symptoms of patients with crohn's leukotriene receptor Erythromycin inhibits cYP3A The disorder. (st-systemtronic.com)
- Patients with type 2 diabetes have increased cancer risk, although the risk association of cancer with antidiabetes drugs remains controversial ( 1 ). (diabetesjournals.org)
- In support of these findings, epidemiological studies have reported reduced cancer risk ( 9 ) and associated mortality ( 10 ) in type 2 diabetic patients treated with metformin compared with other antidiabetes drugs. (diabetesjournals.org)
- The primary lesion in some patients is known to occur in the cells' initial handling of the major cholesterol-carrying lipoprotein of plasma. (elsevier.com)
- Stretch receptors on the main effects of polyuria, obesity in patients a remediable and hypertriglyceridaemia. (freejobaware.com)
- In patients with immunophilins and their absorption, reducing absorp- tion of h1-receptors. (freejobaware.com)
- These drugs usually come with written directions for patients and should be used only as directed by the prescribing physician. (encyclopedia.com)
- The Patients suffered from various factors and cholesterol is one of the major sources of diseases. (scribd.com)
- The FDA ordered that "black box" warnings should be on the most widely prescribed drugs, and that patients should receive medication guideline material. (pharmacytimes.com)
- 6. Lipoprotein is a huge advance from the left parotid gland and may enhance the patients conditions (eg, carotid disease, renal dysfunction, or cirrhosis of the patient, restoring chest wall compliance and adherence. (suagm.edu)
- Two major trials are still ongoing: FOURIER (evolocumab, 27,000 patients) and ODYSSEY OUTCOMES (alirocumab, 18,000 patients), with Montefiore actively enrolling patients in the latter. (yu.edu)
- The drugs are projected to cost between five and ten thousand dollars-or more-annually per patient and will likely be accessible only to a subset of high-risk patients, at least initially. (yu.edu)
- Whether insurance companies will willingly pay for these drugs for a wider group of patients remains to be seen. (yu.edu)
- Still, due to the efficacy of these drugs as shown in trials, and their low side-effect profile, they are eagerly awaited by doctors who treat those with heart disease and their patients. (yu.edu)
- The major intracellular nucleoside reverse transcriptase from poisons and various vitamin d. (imagenenaccion.org)
- These data suggested that codelivery of anti-miR21 and chemotherapeutic agents by HMNs might be a promising strategy for antitumor therapy, and could restore the drug sensitivity of cancer cells, alter intracellular drug distribution, and ultimately enhance chemotherapeutic effects. (dovepress.com)
- My wife and for the current such as blatant gynaecomastia, severe steroid acne behaviour and alteration of the intracellular translocation of calcium via the ryanodine receptor. (3riversstadium.com)
- Pravastatin also inhibits the synthesis of very-low-density lipoproteins, which are the precursor to low-density lipoproteins (LDL). (wikipedia.org)
- Although cholesterol is an extremely important biological molecule with a major role in membrane structure as well as a precursor for the synthesis of steroid hormones and bile acids, excessive cholesterol, is involved in atherosclerotic lesions. (biomedcentral.com)
- The mechanism(s) of this effect is believed to involve both reduction of the synthesis of Low Density Lipoprotein (LDL), and an increase in LDL catabolism as a result of induction of the hepatic LDL receptors. (medisave.ca)
Farnesoid X Recept2
- The Farnesoid X receptor (FXR) is a member of the nuclear receptor superfamily and has emerged as a key player in the control of multiple metabolic pathways. (ahajournals.org)
- Ananthanarayanan M, Balasubramanian N, Makishima M, Mangelsdorf DJ, Suchy FJ (2001) Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. (springer.com)
- The discovery of proteins regulating the activity of the low-density lipoprotein receptor has been a major breakthrough in the development of new cholesterol-lowering drugs. (dovepress.com)
- Since the liver plays a major role in regulating circulating LDL, it is usually of interest to measure the effects of drug or dietary interventions on these proteins in liver. (biomedcentral.com)
- HMG-CoA reductase and the LDL receptor are clear examples of such proteins. (biomedcentral.com)
- Eukaryotic transport proteins in drug action and resistance. (frontiersin.org)
- Many preparations that would possibly via stimulatory g-proteins leukotriene receptor. (imagenenaccion.org)
- Many preparations that would possibly via stimulatory g-proteins leukotriene receptor what to do for cymbalta withdrawals Dinoprostone is replacement therapy of vitamin k-dependent. (imagenenaccion.org)
- Approximately 50% of the drug is bound to plasma proteins. (springer.com)
- Acid SMase has been shown to accelerate atherosclerotic lesion progression through promoting aggreation of lipoproteins to arterial walls. (wikipedia.org)
- Lipoproteins are major players in the development and progression of atherosclerotic plaques leading to coronary stenosis and myocardial infarction. (biomedcentral.com)
- In agreement with the finding of no changes in plasma LDL-C, there were also no differences for the expression of HMG-CoA reductase or the LDL receptor among groups. (biomedcentral.com)
- These correlations suggest that monocytes can be used in humans as an index for liver to assess diet and drug effects on the expression of HMG-CoA reductase and the LDL receptor. (biomedcentral.com)
- Simultaneously, simvastatin-treated mice had a 2.9-fold increase in retinal expression of Cd36 , the major receptor clearing oxidized low-density lipoproteins from Bruch's membrane. (aspetjournals.org)
- The reversal of drug resistance by coloaded HMNs might be attributed to the suppression of miR21 expression and the related antiapoptosis network. (dovepress.com)
- In particular, we are elucidating the pathways leading from the interaction of such factors with their receptors, through the signalling cascades, to the control of gene expression in the nucleus and the subsequent regulation of cellular processes. (cardiff.ac.uk)
- A 2018 British analysis of 10 studies involving more than 77,000 participants revealed that taking Omega-3 supplements for an average of four years "had no significant association with reductions in fatal or nonfatal coronary heart disease or any major vascular events. (mnn.com)
- But generally, studies looking at diabetes drugs have not shown a benefit on larger-scale complications such as coronary disease or heart failure. (medpagetoday.com)
- Familial hypercholesterolemia, a widespread human genetic disorder implicated in vascular and coronary disease, has had no laboratory animal counterpart that would enable the pathogenesis to be analyzed and drugs to be tested in vivo. (elsevier.com)
- The major side effect of stimulating the cartilage matrix and inhibiting dna methyltransferase, which causes a mild to moderate chronic obstructive pulmonary disease copd, coronary artery disease and the potential advantages of hfy, no significant long term treatment of the potential. (roanokechowan.edu)
- changes Are compared for story of coronary receptor plaque been for the pathology of Maximum arteries. (sixpersimmons.com)
- These trials have shown that these drugs lower LDL cholesterol by more than 50 percent, and the data preliminarily suggest that they reduce heart attack and acute coronary syndromes and save lives. (yu.edu)
- After a seemingly unstoppable rally since the US launch of HoFH (Homozygous familial hypercholesterolemia) drug Juxtapid (lomitapide), Aegerion Pharmaceuticals (NASDAQ: AEGR) finally "cooled off" to some extent, although it's worth noting that the CHMP decision contained very positive commentary regarding the drug's efficacy in the treatment of high cholesterol. (biomedreports.com)
- We have now identified LDL receptors on glioblastoma multiforme tumor cells that can serve as specific molecular targets,' says Trudy Forte, a specialist in lipoprotein research with joint appointments in Berkeley Lab's Life Sciences Division and CHORI. (lbl.gov)
- Because these LDL receptors are sparse in normal human brain tissue but elevated on the tumor cells, our synthetic nano-LDLs can deliver drugs to the glioblastoma multiforme tumors while sparing healthy cells. (lbl.gov)
- Tumor cells generally have high cholesterol requirements as they are rapidly dividing, and LDLs are the major transporters of cholesterol in the plasma,' explained Forte. (lbl.gov)
- Furthermore, the codelivery of anti-miR21 and NLS-Dox by HMNs showed synergistic antiproliferative effects in MCF7/ADR-bearing nude mice, and was more effective in tumor inhibition than other drug formulations. (dovepress.com)
- This requires first learning whether the tumor stem cells in culture express LDL receptors, and next establishing a selection or screening procedure to identify receptor-deficient mutants in mutagenized cell cultures. (elsevier.com)
- Attinkara R, Mwinyi J, Truninger K, Regula J, Gaj P, Rogler G et al (2012) Association of genetic variation in the NR1H4 gene, encoding the nuclear bile acid receptor FXR, with inflammatory bowel disease. (springer.com)
- A specific pediatric study within the project focused on a lifestyle intervention on overweight children with variations in the melanocortin 4 receptor gene. (europa.eu)
- The prices of the two drug (patient/year) are extremely high too - at $295,000 and $176,000. (biomedreports.com)
- Aegerion retains full rights to the most efficacious drug for a deadly and rare orphan indication, which allows the company to justify extremely high prices for the drug while enjoying a competitive advantage against ISIS. (biomedreports.com)
- The cells express the cell surface major histocompatibility complex class I antigen, H-2 k of the parental cell line, and express Factor VIII related antigen, high affinity receptors for low density lipoprotein and vascular cell adhesion molecule (VCAM). (atcc.org)
- 5 The metabolic syndrome has been defined by the National Cholesterol Education Program as a cluster of at least 3 of 5 criteria: insulin resistance and glucose intolerance, abdominal obesity, hypertension, low high-density lipoprotein (HDL) cholesterol, and hypertriglyceridemia. (ahajournals.org)
- The current explosion of interest in sophisticated genomic technologies, computerised robotics and high throughput screening of diverse molecular libraries appears to have been associated with a reduction in research productivity in recent years, as judged by the rate of new drug approvals. (ddw-online.com)
- If, today in mid-2003, one walks the halls and corridors of pharma and biotech research centres worldwide, peering through security glass at gleaming laboratories with micro-array robots, high throughput assay instrumentation, bioinformatics databases on multiple LCD screens, one is left with the thought: has building new drug molecules been pushed to one side by the drive to measure, record, archive and retrieve information? (ddw-online.com)
- However, the actual number of effective drugs is very low, most of them having high toxicity, a situation that has worsened by the development of resistance to almost all of them. (frontiersin.org)
- In this study, we aimed to develop new high-density lipoprotein-mimicking nanoparticles (HMNs) for coencapsulation and codelivery of this potential combination. (dovepress.com)
- But OCA's clinical success comes with some major liabilities such as pruritus, high-density lipoprotein cholesterol (HDL c ) lowering, low-density lipoprotein cholesterol (LDL c ) increase, and a potential for drug-induced liver toxicity. (springer.com)
- The results show that the teratocarcinoma cells do in fact have specific high-affinity LDL receptors which are similar to those reported for fibroblasts and the parenchymal cells of specialyzed tissues and different from those of phagocytic cells. (elsevier.com)
- Only LDL and not high density lipoprotein (HDL) was bound. (elsevier.com)
- Correlation between the low-density lipoprotein and Non- high-density lipoprotein was assessed by applying Cramer V and phi. (freethesaurus.com)
- Measurement of low-density lipoprotein particle size by high-performance gel-filtration chromatography. (freethesaurus.com)
- Low-density lipoprotein (LDL), referred to as `bad' cholesterol, and high-density lipoprotein (HDL), referred to as `good' cholesterol. (freethesaurus.com)
- These regulatory factors may be potential targets in high density lipoprotein-based drug discovery. (bvsalud.org)
- Aureus with an arch abnormality in whom systemic salicylates are contraindicated, combination hormonal contraceptive hdl, high density lipoprotein sr b, scavenger receptors therapeutic lifestyle changes for signs of infection in neonates due to lymphopenia extremely rare. (roanokechowan.edu)
- Determine the type most often associated with myelosuppression, fatigue, nausea, or lightheadedness often occur in response to high renin and angiotensin ii recep- tor antagonist varies with drug analgesics maintain comfort related to the surgical defect is closed in layers. (suagm.edu)
- The drugs have been studied in FH cases-those with previous heart disease or at high risk of it. (yu.edu)
- In order to improve the bioavailability and reduce the toxic and side effects, brain targeting of amaryllidaceous alkaloids was enhanced by considering low density lipoprotein (LDL) receptors of blood-brain barrier (BBB) endothelial cells as therapeutic targets. (deepdyve.com)
- The argument is often made that the sheer volume of bio-data being discovered and the sophistication of the bio-informatics tools used to uncover relationships within it will inevitably lead over the years to the identification of a vast array of new drug targets. (ddw-online.com)
- Curr Drug Targets. (mcmaster.ca)
- In this mini-review, we highlight the most recently identified loci that have predicted roles in the vessel wall and provide genetic context for pre-existing therapies as well as new drug targets informed from GWAS. (frontiersin.org)
- Clonidine is a blood pressure drug that targets the a2 adrenergic receptor. (blogspot.com)